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Histone post-translational modifications have been implicated in many 
biological functions and diseases and serve an important role in epigenetic 
regulation of gene expression. Aberrant modulations in histone post-translational 
have been suggested to occur in the brain as part of Alzheimer’s disease (AD) 
pathology, consistent with the epigenetic blockade of neurodegeneration. This 
dissertation details the development and optimization of unique protein standards 
for quantification, called quantification concatamers, for the absolute 
quantification of histone deacetylase isoforms in human frontal cortex with AD, 
human neural retina with AD and age-related macular degeneration, and whole 
brain hemisphere of a 5XFAD mouse model of AD. Histone deacetylases are 
enzymes responsible for the deacetylation of histones, which can directly 
regulate transcription, and have been implicated in AD pathology. In addition to 
measuring isoforms of histone-modifying enzymes, measurements of post-
 
 
translational modifications on histones were also obtained for whole hemispheres 
of brain from 5XFAD mice and frontal cortex from human donors affected with 
AD. For the changes in post-translational modifications observed, structural 
mechanisms were proposed to explain alterations in the DNA-histone affinity in 
the nucleosome, which can modulate gene expression. Measurements and 
structural mechanisms were consistent with the global decrease in gene 
expression observed in AD, which supports the data. This body of work aims to 
better elucidate the epigenetic pathology of AD and to aid in identification of 
histone-modifying enzymes involved in AD pathology for drug targets and 
treatment options. Currently, there are no treatments that prevent, delay, or 
ameliorate AD, stressing the crucial importance of AD pathology research and 
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Chapter 1: Introduction 
1.1 Neurodegeneration 
 The brain is a complex organ responsible for our learning, memory, motor 
control, cognition, homeostasis, motivation, and the way we perceive the world 
around us. The human brain is highly developed relative to other vertebrates; 
humans have the largest ratio of brain mass to body mass of any vertebrate [1]. 
A human brain contains approximately 86 billion neurons and trillions of 
synapses [2], establishing an extensive signaling network. While the human brain 
is only about 2% of the total body mass, it accounts for nearly 20% of body 
energy consumption due to the high metabolic demand of the neurons [2]. 
Despite the capabilities and nourishment of this vital organ, it is susceptible to 
degenerative conditions that can be debilitating and deadly. 
Neurodegeneration is a broad term that describes numerous conditions of 
deterioration that affect neuronal health. Progressive degeneration of the brain 
can lead to debilitating problems, most commonly ataxia, dementia, and death. 
Of the 25 recognized neurodegenerative diseases, the majority are associated 
with specific protein amyloids or aggregates (Table 1.1) [3]. Diseases caused by 
protein amyloids or aggregates are protein conformational diseases where 
misfolding of soluble proteins typically generates highly ordered fibrillar 
aggregates [4]. When these aggregates are found in the extracellular 
environment, they are commonly referred to as plaques. Amyloid fibrils may 
occur within the cell and are referred to as intracellular inclusions, though their 
structure and morphology may be consistent with those present extracellularly 
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[5]. About 85% of neurodegenerative diseases are sporadic, such as Alzheimer’s 
disease (AD), while approximately 10% are hereditary and are the result of 
genetic mutations [4]. Additionally, 5% of neurodegenerative diseases are 
transmissible, such is the case for spongiform encephalopathies caused by 
infectious prions [4]. There have also been reports of acceleration of amyloidosis 
in mice by injection or ingestion of preformed fibrils, suggesting that amyloid 
formation is increased by the presence of amyloid [6,7]. 
 
Table 1.1 - Neurodegenerative diseases [3] 
Disease Protein/Peptide Aggregate 
Alzheimer’s disease (AD) amyloid β, tau 
Parkinson’s disease α-synuclein 
Dementia with Lewy bodies α-synuclein 
Multisystem atrophy DJ-1 
Frontotemporal dementia tau 
Amyotrophic lateral sclerosis 
SOD1, DNA/RNA binding proteins co-
localizes with TDP-43 and ubiquitin 
Frontotemporal lobar degeneration 
DNA/RNA binding proteins co-localizes 
with TDP-43 and ubiquitin 
Huntington’s disease Huntingtin 
Polyglutamine diseases ataxins, atrophin-1, androgen receptor 
Prion diseases prion protein 
Familial amyloidotic polyneuropathy transthyretin, apolipoprotein A1, gelsolin 
Serpinopathies (familial encephalopathy) neuroserpin 






The primary sequence of a protein generally dictates a specific folded 
structure that allows for the protein to function. Misfolding of proteins is often 
mitigated by chaperones under normal conditions. Occasionally, aberrant 
misfolding of proteins can produce very stable amyloids that are resistant to 
refolding and degradation [8]. Amyloids possess a β-sheet structure that is 
usually more thermodynamically stable than the native folded protein [9]. 
Antiparallel stacking of twisted pleated β-sheets of monomers forms a 
hydrophobic core along the fibril axis that facilitates formation of higher ordered 
structures of oligomers and mature fibrils [10]. The heterogeneity of amyloid 
fibrils varies their toxicity and more recent research has shown that amyloid 
oligomers may be even more cytotoxic than originally thought [11]. An illustration 
of heterogeneity in amyloid assemblies is presented in Figure 1.1 [8]. Amyloid 
plaques can also contain other components in addition to amyloids, including 
apolipoproteins, collagen, glycosaminoglycans, metal ions, and glycoproteins 
[12]. Association between plaque constituents and pathology of amyloidosis in 




Figure 1.1 - Heterogeneity in amyloid assemblies. 
Amyloid monomers are structurally dynamic and adopt several conformers, which may 
associate into distinct oligomeric structures and aggregates that are structurally stable. 
Cytotoxicity and other physiological implications vary by amyloid conformer and level of 
assembly [8].  
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1.2 Alzheimer’s Disease 
1.2.1 Prevalence and Impact 
Alzheimer’s disease (AD) is the leading neurodegenerative disorder and 
the sixth leading cause of death in the US [13]. AD accounts for over 80% of 
cases of dementia [13], which most frequently affects the senior population. AD 
affects approximately 13% of people over the age of 65 years and 45% over 85 
[13]. Of the 5.3 million individuals with AD in the US, two-thirds are women [13]. 
Additionally, Hispanic and black ethnicities are more likely to develop AD than 
whites [13]. With the increasing population and advancements that have enabled 
people to live longer, more cases of AD are appearing. If current trends persist, 
the number of AD cases in the US will triple to 13.8 million in 2050 [13]. 
Unfortunately, AD is the only cause of death in the top ten in the US that cannot 
be prevented, slowed, or cured. 
In 2015, AD will cost the US $226 billion and is projected to cost $1.1 
trillion by 2050 [13]. Two-thirds of the cost for AD is provided by Medicare and 
Medicaid [13]. AD is the most financially costly disease [13], owing to the long-
term care and lack of successful treatments. If a treatment were available now 
that could delay the onset of AD symptoms for only 5 years, Medicare and 
Medicaid would save an estimated $42 billion in the year 2020 alone [13]. 
Currently, for every $310 of Medicare and Medicaid spent on AD, there is only $1 
being spent on research at the National Institutes of Health (NIH). The US 
government is aware of the rising number of cases and the financial burden on 
the country and, therefore, has created initiatives and increased NIH spending. 
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The NIH received a $45 million increase in AD research spending in 2013 and 
another $100 million in 2014. Clearly, the concern for treatment options for AD 
has been realized. However, the causation of sporadic AD remains unknown, 
keeping drug targets elusive. 
1.2.2 Features of AD 
 Dementia is a defining symptom of AD that is often, and erroneously, 
generalized as memory loss. While memory loss is a component of dementia, 
dementia also includes impairment of cognition and social abilities. On the 
molecular level, hallmarks of AD are extracellular plaques of Aβ and intracellular 
neurofibrillary tangles (NFT) of tau protein. 
Staging of AD is an important concern when comparing datasets obtained 
from patients. There are two main methods of staging AD severity in acceptance, 
Clinical Dementia Rating (CDR) and Braak staging. As the name implies, CDR is 
focused on the severity of the dementia to assess how advanced the disease is 
for a patient. For CDR, there are numerous questions in various categories that 
are answered in a patient interview. The question categories are memory, 
orientation, judgement and problem solving, community affairs, home and 
hobbies, and personal care. Answers are scored by category and a composite 
score is provided using an algorithm [14] to provide a CDR of none (0), 
questionable (0.5), mild (1), moderate (2), or severe (3). The Braak staging 
focuses on the degree of NFT of tau as well as the regions of the brain affected 
as identified by immunohistochemistry. There are six stages for Braak, from I to 
VI. Braak I/II are characterized by entorhinal NFT distribution, Braak III/IV include 
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limbic distribution, and Braak V/VI includes neocortical distribution [15]. While Aβ 
may be a widely known indicator of AD, it is not used to evaluate severity due to 
the complexity and diversity of Aβ that include diffuse plaques, cored plaques, 
amyloid lakes, and subpial bands [15]. Additionally, different types of deposits 
develop in different brain regions, preventing the use of Aβ for assessment of 
severity [15]. In addition to these two main methods of staging, there are lesser 
used scoring criteria such as the CERAD score proposed by the Consortium to 
Establish a Registry for AD, which also uses NFT density and distribution, and 
the National Institute of Aging’s Reagan Institute Criteria, which combines the 
CERAD and Braak scoring methods to determine the probability that the patient’s 
dementia is attributed to AD. Tissues collected from patients used the patient’s 
score from one of these staging methods to be used to characterize samples for 
pathology research. While there is not a consensus scoring method established, 
variation between scoring methods is minimal and tissue from patients ranked 
with severe AD may be effectively compared to tissue from patients with no 
detectable indicators to identify notable features of AD pathology. 
1.2.3 APP Processing and Aβ 
 The amyloid precursor protein (APP) is a large transmembrane protein 
that is expressed in healthy cells, but most abundantly in neurons and 
concentrated near synapses. Alternative splicing produces three main isoforms 
of APP, which include the full length canonical sequence with 770 amino acids 
and two isoforms with 695 and 751 amino acids. APP(770) and APP(751) are 
primarily found in nonneuronal tissue, while the APP(695) isoform (Figure 1.2B) 
8 
 
is predominately expressed in neurons [16]. In the brain, APP acts as a surface 
receptor for neuronal adhesion, dendrite growth, axongenesis, mobility, and 
transcription regulation. Transcription is promoted by APP binding to APBB1 [17] 
and by binding to Numb to inhibit Notch signaling [18]. However, aberrant 
processing of APP in neurons (Figure 1.2A) is associated with AD. 
APP is translocated into the membrane of the endoplasmic reticulum by 
the 17-amino acid signal peptide on the N-terminus. During maturation in the 
secretory pathway, this signal peptide is removed and APP is moved to the 
plasma membrane of the cell surface. Additionally, APP may be cleaved by α-
secretase and secreted as a soluble fragment APPS-α. Upon cleavage by β-
secretase, the extracellular domain of APP is secreted as APPS-β. The 
remaining portion of APP that contains Aβ can then be cleaved within the 
membrane by γ-secretase to release Aβ. The intracellular domain (ICD) is then 
released inside the cell and may act as a signaling molecule. Other 
transmembrane proteins, such as Notch, CD44, cadherin, low-density 
lipoprotein-receptor-related protein, and receptor tyrosine kinase ErdB4, can also 
be cleaved by γ-secretase and their ICDs can act as signaling molecules within 
the cell [19]. ICDs can activate nuclear signaling pathways, which can result in 
histone modifications and epigenetic changes [20]. 
The function of γ-secretase is actually provided by a complex of proteins: 
presenilin (PS1/PS2), nicasterin (NCT), presenilin enhancer (Pen), and anterior 
pharynx-defective 1 (Aph). All four proteins are required for γ-secretase activity 





Figure 1.2 - APP processing and Aβ in AD. 
(A) Presenilin (PS1/PS2), nicasterin (NCT), anterior pharynx-defective 1 (Aph), and 
presenilin enhancer (Pen) together form the γ-secretase complex, which cleaves APP 
within the membrane region. Aβ is released after β- and γ- secretase cleavage, and can 
associate into soluble oligomers or aggregate into insoluble amyloid plaques. Other APP 
cleavage products act as signaling molecules. (B) The sequence of APP(695) is shown 




The site of cleavage by γ-secretase is variable, with the most frequently cleaved 
site in healthy tissue yielding Aβ1-38. However in AD, Aβ1-42 is predominately 
produced and is more prone to aggregation and oligomerization than Aβ1-38, 
which is likely due to the additional hydrophobic residues 39-42 [11]. Mutations in 
APP and processing enzymes can affect the preference for Aβ1-42 production 
and its pathogenicity. Mutations in APP flanking the Aβ sequence can favor Aβ1-
42, while mutations within Aβ can directly augment the ability to form oligomers 
and aggregates [11]. Similarly, mutations in PS1/PS2, the component of the γ-
secretase complex that contains the proteolytic domain, can also increase APP 
processing. While not all cases of AD contain mutations in proteins associated 
with APP processing, identified mutations are inheritable and have been 
implemented in animal models of amyloidogenesis. 
1.2.4 Sporadic and Familial AD 
 In the vast majority of cases of AD, the disease is considered sporadic or 
late-onset, which the cause is not known. In about 5% of cases, AD can be 
caused by specific point mutations in the genome, known as familial or early-
onset AD. Familial AD was recognized in families where members developed AD 
around the age of forty, noticeably younger than late sixties and older as is 
common in sporadic AD. Observed families had mutations in either APP or 
PS1/PS2 which led to an increased production of Aβ1-42. Several of the 
mutations were named after the location of the families carrying the mutation, for 
example the substitution of isoleucine for valine at position 716 on APP is called 
the Florida mutation. Other common familial mutations are APP K670N/M671L 
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(Swedish), APP V717I (London), PS1 M146L, and PS1 L286V. While specific 
mutations have been identified in familial AD, it is not known what causes AD in 
sporadic cases. There are also polymorphisms in apolipoprotein E (ApoE) that 
are linked to an increased predisposition of AD. However, unlike mutations in 
APP and PS1, ApoE polymorphisms are not indicators of disease, but rather 
increase the propensity of developing AD [16]. However, amyloid production is 
consistent in both sporadic and familial AD, which indicates similarities in 
pathology, while exact etiology may vary by individual. Similar to the 
heterogeneity of cancer, heterogeneity in AD etiology makes AD research more 
complex. The complexity is compounded by difficulty in acquisition of neuronal 
samples from humans. It is not feasible to collect brain biopsies throughout an 
individual’s life to monitor disease pathology, therefore only post-mortem brain 
tissue is available. Due to limitations in acquisition of human brain tissue for 
studying the pathology of AD, animal models are a common tool used to simulate 
AD in humans. 
1.2.5 Animal Models of Amyloidosis 
 Mouse models are the most popular animal models for amyloidosis and 
AD. Mice do not naturally develop AD-like disease, due to either their relatively 
short longevity or murine biology; therefore transgenic mice are created 
specifically to develop AD. Common models include overexpression of human 
proteins with mutations associated with familial AD in humans. One common 
mouse model of AD is called 5XFAD, so called for its five mutations of familial 
AD [22]. 5XFAD mice coexpress two transgenes, yielding high levels of mutant 
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human APP and PS1 in neurons. The transgenes are placed under control of the 
mouse Thy1 promoter, which normally expresses the Thy1 cell surface antigen in 
mature neurons. Mutant APP and PS1 proteins contain the following mutations: 
APP(695) with Swedish (K670N, M671L), Florida (I176V), and London (V717I) 
and PS1 with M146L and L286V. 5XFAD mice preferentially produce Aβ1-42 and 
rapidly develop senile plaques beginning at 1.5 months [22].  Tau neurofibrillary 
tangles are not present in 5XFAD mice. Gliosis begins when mice reach 2 
months and mice also develop extensive neuronal loss. Additionally, these mice 
exhibit severe cognitive impairment, which includes impaired spatial memory, 
stress-related memory, and remote memory stabilization [22]. 
A benefit to using brain from mice rather than humans is that mice may be 
sacrificed quickly by decapitation or cervical dislocation and brain tissue can be 
rapidly collected and flash frozen. This is of particular importance when studies 
are to be performed on PTMs or target molecules that may be degraded shortly 
after death in the presence of heat and the milieu of biological reactions 
occurring in the body. The post-mortem interval, defined as the time between 
death and the tissue being cryopreserved, is typically in the range from several 
hours to a day. Labile PTMs and target molecules may be lost during this time, 
potentially leading to high variability and inaccuracy in measurements. 
Additionally, the quick method of sacrificing mice ensures tissue is not stressed 
in the process, which may happen during the process of death in humans and 
can contribute to inadvertent changes in targets. 
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Nonhuman primate models of AD have demonstrated that they may be 
potentially better at modeling AD pathology. Macaques can develop amyloid 
plaques naturally late in life near 30 years of age. However, considering the time 
for primates to reach advanced age and the percentage of the population that will 
actually display amyloidosis, it is not practical to allow primates to naturally 
develop amyloidosis [23]. Similar to mouse models, injection of Aβ oligomers into 
the brain may be performed to evaluate pathological features. An interesting 
observation is that primate models administered Aβ oligomers develop tau 
phosphorylation and neurofibrillary tangles, which are not present in mice unless 
tau mutants are expressed [24]. Primate studies may be more biologically 
revelant than mouse studies, however, primate studies can be prohibitively 
expensive and mouse models are a more economical approach. Despite animal 
models simulating disease pathology in humans, they are limited to carrying 
familial AD mutations or administration of amyloids, which may have deviances 
from sporadic AD pathology. The majority of research in AD has been performed 
using mouse models, which is ideal for early exploration of disease pathology. 
However, the importance of measurements from human donors with AD should 
be considered to validate observations in animal models. 
1.2.6 Treatments and Therapies 
 There are currently no available treatments that can cure or stop the 
progression of AD. A range of clinical trials have been made that include, 
immunotherapy targeting Aβ, small molecule inhibition of Aβ production and 
aggregation, anti-inflammatory drugs, and inhibition of epigenetic alterations. For 
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immunotherapy, antibodies may be produced either by Aβ-peptide vaccination 
[25] or by passive infusion of anti-Aβ antibodies [26]. Glycosaminoglycans and 
glycolipids associated with aggregation of Aβ have been targeted by small 
molecules and have been shown to reduce plaques in mice [27,28]. Inhibition of 
APP processing enzymes, such as γ-secretase, has also been explored. 
However, due to the role of APP in normal physiology, direct inhibition of γ-
secretase was shown to be deleterious [29]. Anti-inflammatory drugs, such as 
NSAID derivative R-flurbiprofen, have been shown to reduce inflammation 
associated with  AD and indirectly reduce γ-secretase activity [30]. Another class 
of drug candidates that are not directly related to Aβ is HDAC inhibitors. 
Epigenetic changes have been discovered in AD, namely deacetylation of 
histone tails, which affect gene expression. Inhibition of histone deacetylases has 
been shown to reduce cognitive impairment and may be a promising treatment 
[31]. Currently, therapeutic HDAC inhibitors target many HDAC isoforms, a 
particularly detrimental approach when HDAC isoforms are known to have 
different and specialized functions. While many AD therapies are focused on Aβ, 
Aβ may very well be a side product of detrimental intracellular signaling. 
Moreover, sporadic AD does not appear to be caused by mutations in genes 
encoding proteins in APP processing, turning the focus toward intracellular 






1.3 Epigenetics and the Histone Code 
1.3.1 PTMs and Regulation 
 DNA is packaged into the eukaryotic nucleus as chromatin, a structure 
comprised of nucleosomes formed by 146 base pairs of DNA wrapped around an 
octamer of duplicates of histones H2A, H2B, H3, and H4. These histones are 
dynamically modified by post-translational modifications (PTMs), known as the 
“histone code”, which can regulate gene expression. Disruption of these PTM 
codes through the use of inhibitors can affect cell cycle, alter gene expression, 
and induce apoptosis [32]. Studies on monozygous twins suggest that AD may 
be caused by epigenetic factors, an explanation for different outcomes when the 
DNA sequence is conserved [33]. Once acquired, epigenetic factors, such as 
DNA methylation and histone PTMs, can be passed on to offspring cells [34]. 
The most common PTMs in histones are acetylation, methylation, 
phosphorylation, and ubiquitination (Figure 1.3). Histone PTMs are classified into 
two main mechanisms of function: cis and trans. Cis mechanisms modify 
interactions within and between nucleosomes, while trans mechanisms act as 
signals for other proteins to assist in alteration of gene expression, chromatin, or 
other cellular functions [34]. Histone PTMs alter chromatin structure by dictating 
histone-DNA and inter-nucleosome interactions [35]. Changes in chromatin 
structure regulation have been linked to neurodegeneration and AD, giving 







Figure 1.3 - Common histone PTMs. 
There are several PTMs found in histones with acetylation, methylation, and 





 One of the most common PTMs in histones is acetylation. Histone 
acetylation can occur on the primary amine of lysine residues and is catalyzed by 
histone acetyltransferase (HAT) and removed by various histone deacetylases 
(HDACs). The major region of acetylation occurs on the tail region of histones. 
The N-terminal tails of histones extend beyond the nucleosome and are very 
flexible. Additionally, they are rich in positively charged lysine and arginine 
residues. When the histone tail is not hypoacetylated, the positively charged tail 
interacts with the negatively charged backbone of DNA, forming a tighter 
nucleosome structure. The tight nucleosome facilitates packaging into dense 
chromatin, which is less transcriptionally active. Hyperacetylated tails have the 
opposite effect; acetylation neutralizes the charge on the tail region and the 
histone tails act as spacers between nucleosomes, characteristic of 
transcriptional activity. There is strong evidence that HDACs, rather than HATs, 
have significant role in the pathology of neurodegeneration [31]. There are 11 
main isoforms of HDAC with a total of 38 variants in humans. Inhibition of HDACs 
is currently performed with broad inhibitors that affect many or all isoforms of 
HDACs. More studies need to be conducted on HDACs to determine which 
isoforms are associated with disease pathology so that HDAC inhibitors could be 
better targeted for improved safety and efficacy. 
1.3.3 Methylation 
 Lysine residues may be mono-, di-, or tri-methylated and arginine residues 
may be mono- or di-methylated, with arginine demethylation being symmetric or 
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asymmetric. Methylation was originally thought to be an irreversible modification; 
however, it has been shown to be reversible with trimethylation being less 
dynamic than dimethylation and monomethylation. The degree of histone 
methylation often relates to the epigenetic function, but it is not absolute. For 
example, monomethylation is frequently a mark of transcription activation, while 
trimethylation is frequently associated with transcription repression [34]. 
Methylation of histones is catalyzed by histone methyltransferases (HMTs) and 
removal is catalyzed by histone demethylases (HDMs). The demethylase families 
identified predominately act on lysine and are the lysine-specific demethylases 
(LSD/KDM) and the jumonji C-domain-containing iron-dependent dioxygenases 
(JMJD). Despite efforts by others, arginine demethylases are not well 
characterized [39]. Methylation is involved in important biological functions 
including transcriptional regulation, chromatin remodeling, DNA repair, RNA 
processing, signal transduction [34]. The complexity of functions and related 
enzymes stresses the importance of identifying specific sites of methylation in 
histones. Additionally, combinatorial effects from histone PTMs are common with 
methylation [40]. Unlike histone acetyltransferases, histone methyltransferases 
are considerably more site specific and often are responsible for modifying only a 
single site on histones. Thus it is important to identify the specific sites of histone 
methylation and their changes relevant to pathology. 
1.3.4 Phosphorylation 
 Phosphorylation can occur on serine, threonine, and tyrosine residues. 
Histone phosphorylation has been linked to activation and repression of genes 
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based on site of modification and condition of cells [41–43]. The kinases and 
phosphatases that regulate histone phosphorylation are diverse and each site is 
often modified by a single enzyme [44]. Phosphorylation can regulate histone by 
two mechanisms. One method is the phosphorylation mark acts as signal for 
regulatory enzymes to perform a function on the phosphorylated nucleosome 
complex. Another mechanism is the modulation of electrostatic charges on the 
histone. Introduction of phosphate groups increases the negative charge in the 
local environment. Attraction between the negative charge on the phosphorylated 
residue and a neighboring positively charged residue, lysine or arginine, could 
facilitate structural changes. Likewise, negatively charged amino acid residues 
and the phosphate backbone of DNA would be repulsed by the phosphorylated 
residue. It is possible that nucleosome stability could be directly influenced by 
phosphorylation events on the DNA-histone interface. 
1.3.5 Other Histone PTMs 
 There are several other less common PTMs found in histones. 
Ubiquitination is less common than the previously described PTMs, which is 
likely owing to the relatively large size of ubiquitin. The bulky 8.5 kDa protein is 
restricted to modification sites and is mostly found on linker H1 and to a lesser 
extent on the exposed histone core away from the DNA-histone interface. 
Monoubiquitination is the dominant form of histone ubiquitination as 
polyubiquitination is typically associated with degradation. Ubiquitination of 
histone residues has the potential to alter the affinity of histone-histone 
interactions within the nucleosome [45], indicate the presence of DNA damage 
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[46,47], and be a marker for other functional roles. While ubiquitin is 8.5 kDa, 
only its two glycines from the C-terminus remain on modified lysines after 
digestion with trypsin, the most common enzyme for MS proteomics. The 
diglycine modification yields a mass increment of 114.043 Da. Polyubiquitin 
chains are not easily observed in proteomics analysis of histones as the diglycine 
modification is the only remnant of ubiquitination and does not indicate the 
degree of ubiquitination. 
Other less frequent histone PTMs are deamidation, deamination, 
biotinylation, and ribosylation. Deamidation of glutamine and asparagine residues 
is mainly localized to histone H1 variants and is linked to aging [48].. 
Deimination, often called citrullination, of arginine residues is catalyzed by 
peptidylarginine deiminases and this modification is thought to prevent other 
PTMs from occurring on the deiminated arginine [49]. Deimination causes the 
mass to increase by 0.984 Da, which is difficult to distinguish from isotopic peaks 
when using MS. Biotinylation of lysine residues is catalyzed by holocarboxylase 
synthetase and removed by biotinidase. Biotinylation has been implicated in 
gene silencing by changing the nucleosome structure [50]. Ribosylation is of very 
low abundance in histones and is typically not detectable with MS, therefore 
ribosylation studies are usually performed using more sensitive methods, such as 
Western blotting or radioactivity assays [34]. In rare cases, instances of 





1.4 Mass Spectrometry 
1.4.1 Proteomics and Mass Spectrometry 
 Mass spectrometry (MS) is a powerful technique for characterization and 
quantification of biological molecules. In simple terms, MS is the measurement of 
mass to charge (m/z) of an ionized analyte and the associated abundance. MS 
has become an essential tool in proteomics, which is the study of all proteins in a 
biological system. This is because proteomics is more challenging than genomics 
and transcriptomics, due to the dynamic range in protein expression and 
complexity from PTMs, which MS is equipped to address. MS excels in mass 
accuracy, resolution, sensitivity, dynamic range, and speed. Mass accuracy is 
important to correctly identify analytes and resolution is important to observe 
isotopes and modifications with small mass increments, such as deamidation. 
The sensitivity and dynamic range facilitate the measurement of lowly abundant 
proteins, such as HDAC [53], and highly abundant proteins, such as Aβ [54], in a 
single acquisition. MS also allows for rapid analysis and can perform subsecond 
quantifications [55]. 
 MS measurements can be performed on the protein level, called top-
down, or on the peptide level, called bottom-up. Bottom-up analysis typically 
involves fragmentation of the peptide, which can yield various ions that differ by 
the site of fragmentation and localization of charge. The most commonly 
observed ions for peptides fragmented with collision induced dissociation (CID) 
are y-ions, which are formed by fragmentation of amide bonds with the charge 
localized on the C-terminus, and b-ions, which are the result of amide bond 
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fragmentation with charge localized on the N-terminus. Multiple fragments from a 
single peptide enable sequencing of the amino acids residues. While this feat is 
too labor intensive to perform manually for large data sets, there are many 
peptide database search engines that can compile fragmentation data and 
provide a list of peptides and associated proteins and the confidence of the 
peptide identities by fragmentation sequencing and mass accuracy. Peptides 
perform better than proteins in the mass spectrometer because they ionize more 
easily and their relatively small size generates less possible charge states, which 
correlates to greater signal intensity. By contrast, proteins are larger and have a 
much greater heterogeneity in charge states upon ionization, which correlates to 
lower signal for individual charge states when the protein abundance is divided 
among them. A benefit to using top-down is that multiple PTMs can be observed 
on the same protein molecule, permitting a combinatorial assessment of PTMs. 
This is not possible on the peptide level unless both PTMs are present on the 
same peptide, which is not often the case. Depending on the application, it is 
important to use a suitable type of MS instrumentation. 
1.4.2 Instrumentation 
 While MS has been around since the early 1900s, it was not until 
advances in instrumentation in the 1950s and 1960s did MS begin to take shape 
as the powerful analytical method we know today. There are various ionization 
methods, mass analyzers, and detectors used in MS. Of the methods of 
ionization, the most popular for peptides and proteins is electrospray ionization 
(ESI) for several reasons. The majority of MS analyses of complex mixtures 
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involve separation of the peptides or proteins prior to entering the mass 
spectrometer. Liquid chromatography (LC) is most commonly employed for 
peptides and proteins, while gas chromatography and capillary electrophoresis 
are alternatives. LC requires desolvation and ionization, which is provided by 
ESI. When voltage is applied to the solvent containing the sample before or at 
the spray emitter, a voltage of the opposite polarity is applied to the source plate 
to direct the aerosol spray toward the source. The droplets in the aerosol are 
reduced in size by application of a drying gas and heat, which causes the 
droplets to have a reduced volume and concentrated charge. When the 
concentrated charge approaches the Rayleigh limit, the droplets undergo fission 
and iterative cycles of this yield desolvated analytes. 
 Analytes that have entered the mass spectrometer may be separated by 
various mass analyzers. The mass analyzer and parameters used vary based on 
the intended application. Quantification may be performed on any mass 
spectrometer, however, triple quadrupoles and hybrid Qtraps are the preferred 
mass analyzers of choice for targeted quantification. A triple quadrupole consists 
of an initial quadruple which uses Rf frequencies and voltages to isolate a narrow 
window of ions with m/z values near the targeted analyte, while other ions are 
filtered out. The isolated ions, referred to as precursor ions, are then moved to a 
second quadrupole. In the second quadrupole, ions undergo fragmentation by 
CID, which is the bombardment of ions with N2, resulting in increased vibrational 
energy leading to fragmentation of labile bonds. Fragment ions, referred to as 
product ions, are then moved to the last quadrupole which functions as another 
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mass analyzer to isolate only the ions selected for the detector. This platform is 
used for multiple reaction monitoring (MRM), which consists of multiple 
transitions (pairs of product ions and their respective precursor ions) generated 
from CID reactions. MRM is robust and high throughput because the first 
quadrupole may be selecting precursor ions, while the last quadrupole is 
selecting product ions from the previous precursor ion, simultaneously. In 
addition to high throughput, the nature of the acquisition selecting one analyte at 
a time results in greater stability in ion signal, which results in more reproducible 
and accurate quantification. Moreover, the selectivity of MRM reduces complexity 
of ions reaching the detector, preferably to only the target analyte, which results 
in improved sensitivity as low as the attomole level [56]. One disadvantage of 
performing MRM on a triple quadrupole is that the mass accuracy is lower than 
other analyzers. Validation of the identity and retention time of an analyte using 
mass analyzers with greater mass accuracy prior to MRM on a triple quadrupole 
is beneficial when investigating a target in a complex mixture. 
 Characterization of PTMs and determination of intact masses of proteins 
benefits from MS instrumentation with high mass accuracy and resolution. There 
are several mass spectrometers in this category, namely Orbitraps and QTOFs, 
which were included in the work herein. These instruments have the ability to 
measure an analyte with an error in mass of less than 1 ppm. In addition, the 
ability to resolve isotopic peaks and discern between unmodified and deamidated 
peaks can prove highly beneficial depending on the application of the work. 
Orbitraps inject ions into a large barrel-shaped analyzer with a spindle along the 
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axis of the barrel’s length. Ions are injected perpendicular to the spindle and 
undergo harmonic oscillations along the spindle, as a result of the applied 
frequencies, and signals are Fourier transformed for data output. Orbitraps are 
advantageous in their space-to-charge capacity, which accommodates more ions 
for improved signal and increases the dynamic range. Smaller m/z ions have 
greater amplitude of oscillations, which generates larger signal intensity. 
Conversely, large m/z ions have lower signal intensity than observed in other 
mass analyzers, like QTOFs. QTOFs combine a quadrupole with a time-of-flight 
(TOF) analyzer to separate ions by their time to travel a fixed distance. TOF 
analyzers can more easily accommodate larger masses than an Orbitrap, 
however, they are typically not as sensitive. 
1.4.3 Methods of Quantification 
 There are several methods for quantification of proteins in MS, including 
stable isotope dilution, labeling, and label-free approaches. The most common 
and widely preferred methods involve the use of stable isotopes. Incorporation of 
heavy, stable isotopes of carbon, nitrogen, oxygen, or hydrogen can be used to 
increase the mass of a standard or analyte so that it is distinguishable from an 
unlabeled or differently labeled analyte by MS. A labeled and an unlabeled 
peptide have nearly identical chemical properties, which yields consistent 
ionization efficiency for MS and consistent retention time in chromatography. This 
is preferable to using a single reference peptide or protein, as is common with 
Western blotting, for normalization of all target measurements. Labeling of 




in the reaction mixture. 18O incorporates into the carboxylic acid group on the 
terminus of all proteolytic peptides and 18O-labeled peptides can be mixed with 
unlabeled peptides with naturally occurring 16O to obtain an isotopic ratio [57]. 
Isobaric tagging reagents, which also allow multiplexing, can also be used to 
modify specific functional groups [55]. An alternate to schemes involving 
modification of proteins or peptides after translation, stable isotopes may be 
incorporated into proteins or peptides during translation. Synthesized peptides or 
proteins expressed in cell-free expression systems can have heavy-labeled 
amino acids incorporated by replacing specific free unlabeled amino acids with 
labeled amino acids during synthesis. Proteins may also be fully-labeled with 15N 
when expressed in media with 15N as the sole source of nitrogen. Full-length 
labeled proteins are likely the best standards for protein quantification because 
the amino acid sequence flanking a proteolytic digestion site is conserved 
between the biological protein and the full-length labeled standard protein, 
resulting in a consistent rate of cleavage. Moreover, supplementing a sample 
with a full-length protein standard means that all of the measureable peptides are 
contained in the same standard and variations in peptide abundancies are due 
strictly to the inherent cleavage fidelity and ionization efficiency for each peptide, 
not the error in amount of peptide added as seen with individual peptide 
standards. Additionally, protein standards may be added early in the sample 
preparation scheme and are processed in parallel to the protein targets. This 
accounts for sample loss and other errors that may arise during sample 
preparation that are not reflected when supplementing sample with peptide 
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standards near the end of a sample processing scheme. More recently, a hybrid 
between peptide and full-length standards has been developed called a 
quantification concatamer (QconCAT) [58–60]. QconCATs are novel multiplexing 
standards that combine multiple peptides for measurement from many proteins 
and express them as one recombinant protein standard, which benefits from the 





Chapter 2: Optimization of QconCAT Technology 
This chapter contains published work [61]. 
2.1 Introduction 
Multiple reaction monitoring (MRM) mass spectrometry is commonly used 
for targeted protein quantification in complex biological samples.  Quantification 
in MRM assay typically relies on stable isotope-labeled internal standard added 
to the biological sample.  In 2005, a new technology was proposed to produce 
isotopically labeled internal standard for MRM mass spectrometry by genetic 
engineering [59,62] and was termed QconCAT. QconCAT stands for 
quantification concatamer and is an artificial protein expressed from a synthetic 
gene and composed of multiple tryptic peptides (called Q-peptides) from proteins 
targeted for quantification.  As originally proposed [59,62], Q-peptides are directly 
concatenated in the QconCAT.  A pitfall of direct concatenation is that natural 
amino acid sequences surrounding the sites of trypsin-catalyzed cleavage are 
not identical in the QconCAT and the target protein [58].  The efficiency of tryptic 
digestion is likely to be influenced by other residues in close proximity to the 
cleavage site [63–66]. Therefore, differences in the sequence composition 
around the cleavage site in QconCATs and target proteins can cause an error in 
quantification.  To avoid potential quantitative discrepancy, the QconCATs with 
original natural flanking sequences for every Q-peptide were first proposed by 
Kito et al. [67] and then further used by others [68–71]. Nearly identical efficiency 
of trypsin digestion for the target protein and QconCAT with flanking sequences 
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was validated using recombinant clusterin and 15N-labeled clusterin QconCAT 
[69]. Four- or six-amino acid residues flanking sequences were used by different 
researchers [67–71]. Flanking sequences can unfortunately occupy a large 
portion of the QconCAT in addition to the essential Q-peptides.  Therefore, it is 
important to determine experimentally the shortest necessary size of flanking 
sequences that guarantee identical rates of proteolytic excision of the peptides 
from the QconCAT and target protein. 
In the present study, we selected seven Q-peptides from recombinant 
human clusterin and supplemented these peptides with natural flanking 
sequences ranging from none (+0) to six amino acid residues (+6).  These 
peptides were assembled into seven QconCATs in a way that only one specific 
Q-peptide with only one specific length of natural flanking sequence appears in 
each QconCAT.  MRM measurements on 1:1 molar mixture of clusterin and 
individual QconCATs demonstrate that more amino acids included into the 
flanking region may be beneficial for reliable quantification to overcome the effect 
differences in amino acid composition near the cleavage site. 
2.2 Methods 
2.2.1 Expression, Purification, and Characterization of QconCATs 
Synthetic genes encoding seven QconCATs were synthesized by 
Biomatik Corporation (Cambridge, Ontario, Canada).  The design of these 
QconCATs includes seven tryptic peptides (Q-peptides) from human clusterin 
with their natural flanking sequences on both sides of the Q-peptides.  Length of 
the natural flanking sequences ranges from 0 to 6 amino acid residues for each 
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Q-peptide.  Each QconCAT has only one copy of a specific Q-peptide with 
specific length of the natural flanking sequence.  The synthetic genes were 
cloned into the NdeI/HindIII restriction sites of pET21a expression vector in-frame 
to the C-terminal His6-tag.  For expression, the plasmid was transformed into 
One Shot BL21(DE3) and cells were cultivated at 37 °C in M9 minimum medium 
containing 1 g/L 15NH4Cl (Cambridge Isotope Laboratories, Andover, MA) as the 
sole nitrogen source.  Initial inoculation started with 5 mL of LB media and the 
cells were grown for 6-8 h at 37 °C.  Cells were collected by centrifugation at 
20,000 g for 20 min and washed once by 10 mL of 15NH4Cl-containing M9 
medium.  Cells were then transferred to 50 mL of 15NH4Cl-containing M9 medium 
and grown for 12-14 h at 37 °C.  Cells were collected by centrifugation at 20,000 
g for 20 min and washed twice by 100 mL of 15NH4Cl-containing M9 medium.  
Cells were then transferred to 500 mL of 15NH4Cl-containing M9 medium.  The 
expression was induced with 1 mmol/L isopropyl β-D-1-thiogalactopyranoside at 
OD600 of 0.6-0.8 and incubated for an additional 3 h at 37 °C.  Cells were divided 
into 10 portions and harvested by centrifugation at 20,000 g for 30 min. One 
portion of cells was resuspended in 20 mL of lysis buffer (50 mmol/L Tris•HCl, pH 
7.5). Cells were disrupted by sonication and centrifuged at 20,000 g for 30 min.  
The supernatant was discarded.  The pellet was resuspended in 3 mL of urea 
buffer (7 mol/L urea/100 mmol/L NaH2PO4/10 mmol/L Tris•HCl, pH 8.0) and 
15N-
labeled QconCAT was purified on nickel-nitrilotriacetic acid resin (Qiagen, 
Valencia, CA) in batch mode.  The protein concentration of purified 15N-labeled 
QconCAT was measured using the DC Protein Assay kit and bovine serum 
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albumin as a standard. The purified 15N-QconCAT was then aliquoted and kept 
frozen at -80 °C. 
To determine the molecular mass of QconCATs, liquid chromatography-
mass spectrometry (LC-MS) analyses were performed in positive ion mode with 
an Agilent 6550 QTOF (Santa Clara, CA) coupled with an Agilent 1200 HPLC 
(Santa Clara, CA). The QconCAT was eluted from an Agilent ProtID C18 
nanochip (75 µm x 150 mm, 300 nm) over a 10-min gradient from 20% to 80% 
acetonitrile containing 0.1% formic acid at a flow rate of 400 nL/min.  Acquisition 
method in positive mode used capillary temperature 275 °C, fragmentor 180 V, 
capillary voltage 1950 V, and a 500 m/z to 2000 m/z mass window. Mass 
deconvolution was later performed using MagTran 1.0 software. 
2.2.2 Processing of Samples 
20 pmol of human recombinant clusterin (purity ˃ 95%, ProSpec-Tany 
TechnoGene Ltd, Ness Ziona, Israel), 20 pmol of individual QconCAT, and 20 μg 
of bovine serum albumin were mixed in 25 mmol/L NH4HCO3 buffer/1% SDS/10 
mmol/L DTT.  The mixture was incubated at room temperature for 60 min to 
allow reduction of cysteines and was then treated with 55 mmol/L iodoacetamide 
for another 60 min to alkylate the reduced cysteines. Alkylated samples were 
precipitated with chloroform/methanol [72] to deplete salts, urea, and SDS from 
the samples. Protein pellets were then sonicated in 100 µL of 25 mmol/L 
NH4HCO3/0.1% RapiGest and treated with trypsin for 15 h at 37 °C. The 
substrate/trypsin ratio was 10:1 (w/w). After trypsin digestion, the peptide 
samples were treated with 0.5% trifluoroacetic acid for 30 min at 37 °C and 
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centrifuged at 106,000 g for 30 min. After centrifugation, the supernatants were 
dried using a vacuum centrifuge (Vacufuge, Eppendorf AG, Hamburg, Germany). 
2.2.3 LC-MS/MS Analysis 
Dried peptides were reconstituted in 30 µL of 3% acetonitrile/97% water 
containing 0.1% formic acid and 5 µL were used for a single LC-MS/MS run.  
Instrumental analyses were performed on an Agilent Zorbax Eclipse Plus C18 
RRHD column (2.1 mm x 50 mm, 1.8 µm particle) coupled to Agilent 6460 Triple 
Quadrupole LC/MS system (Santa Clara, CA).  Peptides were eluted over a 35-
min gradient from 5% to 50% acetonitrile containing 0.1% formic acid at a flow 
rate of 200 µL/min.  The gradient settings were: 5% to 10% solvent B in 5 min, 
10% to 30% solvent B in 25 min, 30% to 50% solvent B in 5 min, then returned to 
5% solvent B in 5 min.  Solvent A was water containing 0.1% formic acid and 
solvent B was 95% acetonitrile, 5% water, and 0.1 % formic acid.  Acquisition 
method used the following parameters in positive mode: fragmentor 135 V, 
electron multiplier 500 V, and capillary voltage 3500 V.  Collision energy was 
optimized for each peptide using the default equation from Agilent, CE = 0.036 
m/z - 4.8.  Dwell time for all transitions was set at 50 ms. 
2.3 Results and Discussion 
2.3.1 Design of QconCATs 
Selection of Q-peptides has size and composition restraints.  Peptides that 
contain less than eight amino acids are typically omitted because of small m/z 
values.  Peptides with Cys or Met are also avoided due to the existence of 
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various oxidation entities, which could introduce variations in the quantification.  
In the present study, human clusterin (apolipoprotein J) was selected as a model 
protein because this secreted protein has an average mass (52.5 kDa) and 
multiple Cys/Met but allows selection of up to 9 tryptic peptides, which comply 
with Q-peptide selection criteria.  As a first step, the abundance of these Q-
peptides in the tryptic digest of recombinant clusterin was determined and 7 Q-
peptides were selected based on signal intensity.  These 7 Q-peptides were 
named by Q1 (EIQNAVNGVK), Q2 (TLLSNLEEAK), Q3 (SGSGLVGR), Q4 
(IDSLLENDR), Q5 (ASSIIDELFQDR), Q6 (ELDESLQVAER), and Q7 
(VTTVASHTSDSDVPSGVTEVVVK).  They were then supplemented with natural 
flanking sequences ranging from 0 to 6 amino acid residues on both sides of 
each Q-peptide and were arranged in 7 QconCATs in a way that only one 
specific Q-peptide with only one specific length of natural flanking sequence 




Table 2.1 - QconCAT sequences, Q-peptides, and natural flanking sequences. 
Color codes are: (i) Q-peptides are shown in red, natural flanking sequences are shown 
in black, an extra N-terminal sequence for improved QconCAT expression is shown in 









Q-peptide Sequence Flanking sequence length 
Q1 EIQNAVNGVK 0 
Q2 TLLSNLEEAK 1 
Q3 SGSGLVGR 2 
Q4 IDSLLENDR 3 
Q5 ASSIIDELFQDR 4 
Q6 ELDESLQVAER 5 







Q-peptide Sequence Flanking sequence length 
Q1 EIQNAVNGVK 1 
Q2 TLLSNLEEAK 2 
Q3 SGSGLVGR 3 
Q4 IDSLLENDR 4 
Q5 ASSIIDELFQDR 5 
Q6 ELDESLQVAER 6 











Q-peptide Sequence Flanking sequence length 
Q1 EIQNAVNGVK 2 
Q2 TLLSNLEEAK 3 
Q3 SGSGLVGR 4 
Q4 IDSLLENDR 5 
Q5 ASSIIDELFQDR 6 
Q6 ELDESLQVAER 0 







Q-peptide Sequence Flanking sequence length 
Q1 EIQNAVNGVK 3 
Q2 TLLSNLEEAK 4 
Q3 SGSGLVGR 5 
Q4 IDSLLENDR 6 
Q5 ASSIIDELFQDR 0 
Q6 ELDESLQVAER 1 







Q-peptide Sequence Flanking sequence length 
Q1 EIQNAVNGVK 4 
Q2 TLLSNLEEAK 5 
Q3 SGSGLVGR 6 
Q4 IDSLLENDR 0 
Q5 ASSIIDELFQDR 1 
Q6 ELDESLQVAER 2 










Q-peptide Sequence Flanking sequence length 
Q1 EIQNAVNGVK 5 
Q2 TLLSNLEEAK 6 
Q3 SGSGLVGR 0 
Q4 IDSLLENDR 1 
Q5 ASSIIDELFQDR 2 
Q6 ELDESLQVAER 3 







Q-peptide Sequence Flanking sequence length 
Q1 EIQNAVNGVK 6 
Q2 TLLSNLEEAK 0 
Q3 SGSGLVGR 1 
Q4 IDSLLENDR 2 
Q5 ASSIIDELFQDR 3 
Q6 ELDESLQVAER 4 





2.3.2 Characterization of QconCATs 
Purity of QconCATs was estimated by SDS-PAGE (Figure 2.1A) and 
considered to be nearly 100% pure.  No correction for protein concentration of 
QconCATs was made for further MRM analysis and total protein concentration 
determined for the purified QconCATs was used as mg/mL concentration. 
15N isotope incorporation was determined based on MALDI spectra of Q-
peptides by Isotopic Enrichment Calculator (www.nist.gov/mml/bmd/bioanalytical/ 
isoenrichcalc.cfm) [73].  Figure 2.1B shows representative MALDI spectra for two 
Q-peptides from QconCAT #1.  The MALDI spectra for these Q-peptides from 
other QconCATs (from #2 to #7) are summarized in Figure 2.2.  Both peptides 
yielded consistent results and the mean value based on two peptides and three 
analytical replicates was higher than 99% for each QconCAT (Table 2.2). These 
values were accepted as complete labeling and no correction was applied to 
data. 
To determine the molecular mass of QconCATs, LC–MS analyses were 
performed in positive ion mode with an Agilent 6550 QTOF.  Figure 2.1C shows 
a representative spectrum and deconvolution for QconCAT #1.  The related 
spectra for other QconCATs (from #2 to #7) are summarized in Figure 2.3.  
Overall, observed mass of each QconCAT was consistent with calculated mass 
(Table 2.2), indicating full-length expression of QconCAT.  Accordingly, the 
calculated average molecular mass was used to convert mg/mL concentration of 
QconCAT into the mol/L concentration, which was further used to mix QconCAT 





Figure 2.1 - Characterization of QconCATs. 
(A) 100 pmol of purified QconCATs (from #1 to #7) were separated on 12.5% SDS-
PAGE.  The molecular mass standards are shown on the right.  (B)  MALDI spectra for 
two Q-peptides from QconCAT #1, which were used to calculate 15N-incorporation by 
Isotopic Enrichment Calculator (http://www.nist.gov/mml/analytical/organic/ 
isoenrichcalc.cfm).  The MALDI spectra for other QconCATs (from #2 to #7) are 
summarized in Figure 2.2.  (C)  Full-size QconCAT expression was confirmed using 
Agilent 6550 QTOF instrument.  ESI mass spectrum of QconCAT #1 is shown.  The 
insert shows deconvoluted spectrum with observed average molecular mass of 
QconCAT #1.  The spectra for other QconCATs (from #2 to #7) are summarized in 






Figure 2.2 - MALDI spectra used to calculate 15N incorporation. 
Two Q-peptides (Q5 and Q6) were chosen to determine percentile of 15N incorporation. 
Data presented as mean ± SD are summarized in the Table 2.2. 
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#1 99.7 ± 0.08 19427 19425 103 
#2 99.6 ± 0.08 19459 19425 1747 
#3 99.6 ± 0.08 19301 19382 4197 
#4 99.7 ± 0.04 19286 19365 4096 
#5 99.7 ± 0.08 19430 19471 2110 
#6 99.7 ± 0.14 19472 19472 N/A 





















Figure 2.3 - Spectra of intact QconCATs. 
Full-size QconCAT expression was confirmed using Agilent 6550 QTOF instrument. The 
insert shows the spectrum deconvoluted with MagTran 1.0 with observed average 
molecular mass. Observed mass of QconCAT #2 (A) was 19425 Da (19459 Da 
calculated), QconCAT #3 (B) was 19382 Da (19301 Da calculated), QconCAT #4 (C) 
was 19365 Da (19286 Da calculated), QconCAT #5 (D) was 19471 (19430 Da 
calculated), QconCAT #6 (E) was 19472 Da (19472 Da calculated), and QconCAT #7 
(F) was 19231 (19265 Da calculated). 
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2.3.3 Measured Ratios as a Function of Length of Natural Flanking Sequences 
Three MRM transitions for each Q-peptide were selected as previously 
described [74] and are tabulated in Table 2.3.  These transitions were treated as 
independent measurements, each resulting in a ratio value for the corresponding 
Q-peptide. Measurements were performed with three analytical replicates for 
each of two biological replicates, resulting in the total n = 18.  The average value 
for each natural flanking sequence variant of a Q-peptide was normalized to the 
value obtained for the respective 6 amino acid natural flanking sequence of that 
Q-peptide. Normalization was performed to simplify evaluation of the effect of 
flanking sequence length on each Q-peptide as well as to allow for comparison 
between Q-peptides. Data in Figure 2.4 are presented as a mean ± SD and 
plotted versus the length of natural flanking sequence for all seven Q-peptides.  
Recombinant clusterin and QconCAT were mixed at 1:1 molar ratio. If the 
presence of natural flanking sequence is not essential for accurate quantification, 
then all measured ratios should be around 1.0 with CV up to 30% (shown with 
blue dashed lines in Figure 2-4A).  CV of 30% range is typical for MRM assay of 
proteins [75,76] and covers uncertainties associated with measurements of total 
protein concentrations, pipetting during analyte/standard mixing, and biological 
and analytical replicates.  Some data presented herein fit well in this range.  For 
example, Q7 shows little ratio variation associated with the length of natural 
flanking sequences and even absence of natural flanking sequence has the ratio 
(1.05 ± 0.13) similar to the ratio measured for the presence of 6 amino acid 










































































































Figure 2.4 - Measured ratios. 
Recombinant human clusterin was mixed with individual QconCATs at 1/1 (pmol/pmol) 
ratio resulting in seven separate samples. MRM assay for these samples was used to 
determine actual measured ratios for each individual Q-peptide with different length of 
natural flanking sequences. (A) Measured ratios (mean ± SD, n = 18) are plotted versus 
the length of natural flanking sequence for all seven Q-peptides.  Blue dashed lines 
border a section of plot for ratios in the range of 1.0 ± 30%. (B) Data for Q2 (shown in 
red) are used as a representative example to demonstrate how shorter natural flanking 
sequences (shown in black) cause an appearance of random non-original amino acid 
residues (shown in blue) in the close proximity to trypsin cleavage sites.  Related data 
presentation for all of other Q-peptides is summarized in Table 2.4.  
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Table 2.4 – Measured ratios. 
The three transitions from each peptide were treated as independent measurements, 
each resulting in a ratio value for the corresponding peptide.  Measurements were 
performed with three analytical replicates for each of two biological replicates resulting in 
the total n = 18.  Data are presented as a mean ± SD normalized to the +6 natural 








#7 +6 GSKYVNKEIQNAVNGVKQIKTLI 1.00 + 0.31 
#6 +5 VSKYVNKEIQNAVNGVKQIKTLK 0.83 + 0.11 
#5 +4 LVKYVNKEIQNAVNGVKQIKTTN 0.92 + 0.05 
#4 +3 FLVYVNKEIQNAVNGVKQIKNEE 0.53 + 0.06 
#3 +2 GFLVVNKEIQNAVNGVKQIEERK 1.03 + 0.17 
#2 +1 RGFLVNKEIQNAVNGVKQERKTL 0.97 + 0.04 







#6 +6 KTNEERKTLLSNLEEAKKKKEDA 1.00 + 0.13 
#5 +5 TTNEERKTLLSNLEEAKKKKEDF 1.32 + 0.08 
#4 +4 IKNEERKTLLSNLEEAKKKKEYA 0.44 + 0.03 
#3 +3 KQIEERKTLLSNLEEAKKKKARV 0.53 + 0.06 
#2 +2 GVKQERKTLLSNLEEAKKKRVCR 0.82 + 0.02 
#1 +1 VNGVKRKTLLSNLEEAKKVCRSG 0.93 + 0.08 







#5 +6 FYARVCRSGSGLVGRQLEEFL 1.00 + 0.09 
#4 +5 EYARVCRSGSGLVGRQLEEFF 0.62 + 0.08 
#3 +4 KKARVCRSGSGLVGRQLEEWM 1.02 + 0.10 
#2 +3 KKKRVCRSGSGLVGRQLEMNG 0.71 + 0.05 
#1 +2 EAKKVCRSGSGLVGRQLNGDR 1.11 + 0.02 
#7 +1 LEEAKCRSGSGLVGRQGDRID 0.64 + 0.15 







#4 +6 FWMNGDRIDSLLENDRQQTHML 1.00 + 0.05 
#3 +5 EWMNGDRIDSLLENDRQQTHMM 2.05 + 0.08 
#2 +4 LEMNGDRIDSLLENDRQQTHQD 2.20 + 0.02 
#1 +3 RQLNGDRIDSLLENDRQQTDHF 1.26 + 0.07 
#7 +2 VGRQGDRIDSLLENDRQQHFSR 0.63 + 0.06 
#6 +1 GLVGRDRIDSLLENDRQFSRAS 1.74 + 0.15 










#3 +6 MQDHFSRASSIIDELFQDRFFTREP 1.00 + 0.04 
#2 +5 HQDHFSRASSIIDELFQDRFFTRES 0.93 + 0.22 
#1 +4 QTDHFSRASSIIDELFQDRFFTRQA 1.07 + 0.05 
#7 +3 RQQHFSRASSIIDELFQDRFFTAKL 0.62 + 0.06 
#6 +2 NDRQFSRASSIIDELFQDRFFKLRR 0.84 + 0.05 
#5 +1 LENDRSRASSIIDELFQDRFLRREL 1.17 + 0.03 







#2 +6 SQAKLRRELDESLQVAERLTRKYN 1.00 + 0.19 
#1 +5 RQAKLRRELDESLQVAERLTRKYE 1.09 + 0.04 
#7 +4 FTAKLRRELDESLQVAERLTRKDQ 0.68 + 0.08 
#6 +3 RFFKLRRELDESLQVAERLTRQYY 1.08 + 0.12 
#5 +2 QDRFLRRELDESLQVAERLTYYLR 1.26 + 0.02 
#4 +1 LFQDRRRELDESLQVAERLYLRVT 0.62 + 0.02 







































However, we have also observed multiple examples when measured ratios 
strongly deviate from expected 1.0 ± 30% (Figure 2.4).  These deviations did not 
simply correlate with the length of the natural flanking sequence itself.  This 
observation encouraged us to analyze the actual amino acid sequences 
surrounding trypsin cleavage sites because shorter natural flanking sequences 
brought random amino acid residues into close proximity to the trypsin cleavage 
sites. As a representative case, the data for Q2 are shown in Figure 2.4B.  
Related data for all other QconCATs is summarized in Table 2.4.  Figure 2.4B 
allows side-by-side comparison of the ratios for Q2 and these ratios depend on 
the changing pattern of amino acid residues surrounding trypsin cleavage sites, 
with natural flanking residues shown in black and random residues shown in 
blue.  In general, these random amino acid residues can have negative, positive, 
or no effect for trypsin digestion.  Indeed, +1 and +2 flanking combinations for Q2 
do not differ from +6 pure natural flanking sequence.  However, +0 and +6 
combinations have approximately 2-fold difference.  The same is correct for +4 
and +6 combinations.  Some of these deviations can be explained based on so-
called Keil rules (reviewed in [58,77]). For example, if to compare +6 
(KTNEERKTLLSNLEEAKKKKEDA) to +0 (QIKTLIKTLLSNLEEAKCRSGSG), it is 
apparent that omitting most of positive- and negative-charged residues on both 
sides of Q2 in +0 combination improves rate of trypsin digestion and results in 
high yield of Q2 from QconCAT versus yield of Q2 from recombinant clusterin.  
Overall, it gives a measured ratio 0.45 ± 0.05 for +0 combination.  However, 
measured ratios for many other combinations cannot be so simply explained.  
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For example, the difference in flanking sequences between +4 and +5 
combinations is small and hard to be related to Keil rules while the difference in 
ratios is approximately 3-fold. 
Sequence-based analysis of other Q-peptides (Table 2.4) concurs well 
with trends described here for Q2 and can be summarized in two assumptions: (i) 
inclusion of +6 residues natural flanking sequences on Q-peptide mimics well the 
close proximity of trypsin cleavage sites and provides for the most accurate 
quantification of target protein; (ii) shorter natural flanking sequences still could 
be quantitative, in some occasions, such as Q4, Q5, Q6, and Q7, even no natural 
flanking sequences at all (+0 combination) performed quantitatively well (Figure 
2.4A). However this is not a guarantee since random residues brought into close 
proximity of trypsin cleavage sites can have unpredictable effect on efficiency of 
trypsin digestion. Work by others has attempted to provide structural effects on 
cleavage sites as a rationale for deviations from expected Keil rules, such as 
greater trypsinolysis of exposed sites within loop structures and decreased 
trypsin cleavage fidelity near negatively-charged pockets created by bringing 
acidic residues into close proximity in the folded conformation rather than 
proximity within linear amino acid sequence [77]. These contradictions to Keil 
rules on a structural basis cannot be applied to our observations because both 
clusterin and QconCATs were denatured with SDS, thereby reducing structural 
effects on trypsinolysis. While a minor degree of secondary structures may be 
present due to incomplete denaturation by SDS, it is unlikely that it is significant 
enough to impact cleavage by trypsin and, therefore, our observations can be 
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described as being caused by the primary amino acid sequence. Since variation 
between trypsin cleavage fidelity in native protein and QconCAT is not 
completely predictable, several precautionary steps may be considered to reduce 
inconsistencies in quantification. First, and perhaps the most simple method to 
avoid error in measurement, is to include more natural amino acid residues on 
both sides of every Q-peptide. Simple inclusion of more natural amino acids will 
enable more reliable relative quantification to near absolute quantification 
appropriate for measurements within similar samples performed by consistent 
protocols. Second, and perhaps more laborious, is to optimize natural flanking 
sequence length by conducting experiments similar to those provided herein to 
determine the appropriate length of the natural flanking sequence to yield 
consistent 1:1 ratio between QconCAT and analyte for each Q-peptide. 
Optimization would be preferred for QconCATs produced for inter-laboratory 
comparisons and comparisons of protein concentrations between tissues or 
species where more accurate quantitative data is imperative. 
An important observation in the present study is that the randomly 
occurring error of quantification associated with shorter than +6 natural flanking 
sequences was not greater than approximately 2-fold.  Although the wording 
“absolute” quantification is broadly used, MRM quantification with QconCATs is 
often used for “relative” comparison of two (or more) biological samples.  
Acquiring quantification with up to ±2-fold error in both biological samples will not 
change their relative comparison in side-by-side experiments and can justify 
support of QconCATs without natural flanking sequences.  However, there are 
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several applications where truly absolute quantification is important.  For 
example, inter-laboratory comparisons, discovery of post-translational 
modifications, comparison of protein expression levels in different 
tissues/species, and others.  For all of these applications, it would be 
recommended to use more amino acid residues in the natural flanking 
sequences of every Q-peptide to be included into the QconCAT. 
2.4 Conclusions 
Although natural flanking sequences for Q-peptides are not directly used 
for quantification and occupy a large portion of the QconCAT, it appears that 
including more natural amino acid flanking residues is better for reliable 
quantification. It is evident from our observations that trypsin cleavage is not 
solely dependent on the length of natural amino acid flanking sequence in the +0 
to +6 amino acid residue range, but rather on the properties of amino acids 
residues found within that range. Furthermore, effects of amino acid composition 
within the flanking sequence cannot be predicted entirely by Keil rules of trypsin 
cleavage. I suggest performing experiments similar to those performed herein to 
optimize each Q-peptide flanking sequence to confirm accurate quantification or 
to simply include additional natural amino acid flanking residues. When it is 
necessary to have a large number of Q-peptides, it is practical to select an 
appropriate number of amino acids, such as four, in the flanking sequence to 





Chapter 3: Quantification of Histone Deacetylase Isoforms 
This chapter contains published work [53]. 
3.1 Introduction 
One of the most common PTMs in histones is acetylation. Removal of 
acetyl groups from histone tails is chiefly catalyzed by histone deacetylases 
(HDACs). HDACs are categorized into eleven main isoforms, which are further 
broken into thirty-eight sequence variants by truncations, deletions, and 
substitutions of the canonical sequence [78]. Several HDACs have been linked to 
memory impairment and dementia [79,80], a hallmark of AD, and it has been 
demonstrated that global deacetylation of histones and overall activity of HDACs 
is increased in AD [81]. In addition to histones, HDACs are also known to modify 
over 50 non-histone proteins [81]. The majority of information on effects of HDAC 
isoforms comes from overexpression and knockouts of HDACs in murine models 
of AD. While mice may be more practical for neurodegeneration research 
involving manipulation of HDACs, it is still a non-human model for familial, early-
onset AD. Most AD cases are considered sporadic or late onset, and while they 
may have the same key characteristics like dementia and protein aggregation, 
pathogenesis may vary from familial AD [82]. A connection between HDACs and 
AD has been established in mouse models; however, little information exists on 
changes in specific isoforms and the significance of their effects on AD pathology 
in humans.  
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HDAC inhibitors (HDIs) have shown improvement of AD-related 
symptoms; however, these are broad class HDIs, which do not target specific 
isoforms. If a long-term regimen of broad class HDIs were prescribed to prevent 
or stop the progression of AD, there may be deleterious side effects in other 
HDAC-associated pathways. For example, HDIs in mouse models have 
demonstrated improvement in memory [79,83,84], yet deficiency of either 
HDAC4 or HDAC5 impairs memory [85,86]. Specific knowledge of isoforms 
directly related to AD is imperative for treatment specificity and safety [31]. 
Various methods for assessment of HDAC levels have been reported, 
including  quantitative real-time polymerase chain reaction [87,88], in situ 
hybridization [89], Western blotting [87,88], and immunohistochemical staining 
[90]. However, these semi-quantitative methods are unable to provide absolute 
quantitative data on the protein level of HDAC isoforms and isoform-specific 
quantification of HDACs remains elusive. Mass spectrometry (MS) provides the 
potential to perform targeted absolute quantification of protein isoforms. Synthetic 
peptides and full-length proteins labeled with stable isotopes are commonly used 
in MS-based protein quantification. Due to the large number of HDAC isoforms, it 
is less practical to use synthetic peptides or express full-length protein for each 
isoform. An alternative is performing quantitative measurements using 
QconCATs as internal standards [58,60]. QconCATs are standard proteins 
comprised of proteolytic peptides used for quantification and they may include 
the respective natural flanking sequences from targeted proteins. Previous work 
has shown applicability of QconCATs for measurement of abundant proteins in 
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neural tissues, such as amyloid precursor protein [91], apolipoprotein E [92], 
clusterin [69], PICALM [93], and ubiquitin carboxy-terminal hydrolase L1 [71]. 
QconCATs used in this study exceed past number of proteins measured and 
cover 25 sequence variants of HDACs, proteins with significantly lower 
abundance than those previously reported. 
The goal of the present study was to determine whether multiplexing 
QconCAT technology could be applied to quantification of HDAC isoforms in 
different neural tissues in normal and disease state. Using QconCAT technology 
[60], three 15N-labeled standard proteins were produced to measure all selected 
HDAC variants. Human and mouse brain and human retina samples were 
supplemented with these standard proteins and protocols for sample processing 
were optimized and analytically characterized. Measurements in human frontal 
cortex and human retina give insight into abundance of particular isoforms in 
different neural tissues in normal and disease states. Mouse brain, a common 
model for neurodegenerative phenotypes, shows HDAC profiles in comparison to 
human tissue. Quantification of HDAC isoforms in AD-affected human brain and 
age-matched controls also contributes to our knowledge of disease-associated 
isoforms that may be of value for HDIs therapies for AD. Furthermore, the 
developed analytical approach is broadly applicable to quantitative analysis of 







3.2.1 Expression, Purification, and Characterization of QconCATs 
Tryptic peptides for all HDAC isoforms were predicted and 64 HDAC-
specific peptides with respective four-amino acid long natural flanking sequences 
were compiled into three QconCAT proteins (Figure 3.1 and Tables 3.1, 3.2, 3.3). 
Amino acid sequences were translated into cDNA and cloned into pET21a 
expression vectors with NdeI/HindIII restrictions sites by Biomatik Corporation 
(Cambridge, ON, Canada). Expression vector, which included His6-tag expressed 
on C-terminus of the protein, was transformed into One Shot BL21(DE3) E. coli 
and cells were cultivated at 37 °C in M9 minimal medium containing 1 g/L 
15NH4Cl as the sole nitrogen source. Initial inoculation began with 5 mL LB media 
and cells were grown for 6 h at 37 °C. Cells were pelleted by centrifugation at 
20,000 g for 20 min and washed with 10 mL of 15NH4Cl-containing M9 medium. 
Cells were then transferred to 50 mL 15NH4Cl-containing M9 medium and grown 
for 12 h to 14 h at 37 °C. Cells were collected by centrifugation at 20,000 g for 20 
min and washed twice by 100 mL 15NH4Cl M9 medium. Cells were then 
transferred to 500 mL 15NH4Cl M9 medium. Expression was induced with 1 
mmol/L IPTG at OD600 of 0.6 to 0.8 and incubated for an additional 3 h at 37 °C. 
Cells were divided into 10 portions and harvested by centrifugation at 20,000 g 
for 30 min. One portion of cells was resuspended in 20 mL of lysis buffer (50 
mmol/L Tris, pH 7.5). Cells were lysed by sonication and centrifuged at 20,000 g 




Figure 3.1 - QconCAT design overview. 
Tryptic peptides from HDACs were predicted and screened for peptides suitable for 
MRM quantification. Natural flanking sequences consisting of four amino acids on each 
side of tryptic Q-peptides were included. A cDNA construct encoding the concatamer of 
these peptides was inserted into pET21a expression vector by Biomatik. BL21 (DE3) 
cells were transformed with plasmid and QconCATs were expressed with His6-tag and 
purified by nickel-nitrilotriacetic (Ni-NTA) acid resin. 
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Table 3.1 - HDAC QconCAT#1 sequence and peptides for quantification. 
 


























GMCKVAINWSGGWHHAKKDEA HDAC8(1-3, 5) 
GKGRYYSVNVPIQDGIQDEKYYQI HDAC8(1-2, 4-5) 
SVLKEVYQAFNPKAVVL HDAC8(1, 4) 
ERHRIQQILNYIKGNLK HDAC8(1, 4) 
 
Molecular weight: 45547.3 Da 14N (46125.6 Da 15N) 




Table 3.2 - HDAC QconCAT#2 sequence and peptides for quantification. 
 

















IWSRLQETGLLSKCERI HDAC5(1, 3) 






ALERTVHPNSPGIPYRTLEP HDAC7(1, 3-8) 
IPYRTLEPLETEGATRSMLS HDAC7(1, 3-8) 
PLRKTVSEPNLKLRYK HDAC7(1, 3-8) 
TTERLSGSGLHWPLSRTRSE HDAC7(1, 3-8, 10) 







Molecular weight: 48288.6 Da 14N (48929.7 Da 15N) 




Table 3.3 - HDAC QconCAT#3 sequence and peptides for quantification. 
 














QEDRAPSSGNSTRSDSS HDAC9(1, 3-8) 
IWSRLQETGLLNKCERI HDAC9(1-2, 4-7) 
LDPRILLGDDSQKFFSS HDAC9(1-2, 4-7) 





SLAREEALTALGKLLYL HDAC10(1-2, 4) 









Molecular weight: 42602.3 Da 14N (43166.6 Da 15N) 





Pellet was resuspended in 3 mL urea buffer (7 mol/L urea; 0.1 mol/L NaH2PO4; 
0.01 mol/L Tris•HCl; pH 8.0) and 15N-labeled QconCAT was purified on nickel-
nitrilotriacetic (Ni-NTA) acid resin (Qiagen, Valencia, CA). Purified 15N-labeled 
QconCAT was loaded onto a SpinTrap G-25 spin column (GE Healthcare, 
Waukesha, WI) to exchange buffer into 25 mmol/L NH4HCO3 with 1% SDS. 
Protein concentration was measured in presence of 1% SDS using detergent-
compatible DC Protein Assay kit and bovine serum albumin as standard.  Final 
QconCATs were aliquoted and stored at -80oC. Purity was estimated by 10% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
ImageJ software (http://www.imagej.nih.gov/ij/). 
Intact masses of QconCATs were determined experimentally using an 
Agilent 6550 QTOF and mass deconvolution with MagTran 1.0 software. 
QconCATs were eluted from an Agilent ProtID C18 nanochip (75 µm x 150 mm, 
300 nm) over 10 min gradient from 20% to 80% acetonitrile containing 0.1% 
formic acid at a flow rate of 400 nL/min. Acquisition method in positive mode 
used capillary temperature 275 °C, fragmentor 180 V, capillary voltage 1950 V, 
and a 500 m/z to 2000 m/z mass window. QconCAT characterization on the 
peptide level was performed using an Applied Biosystems 4700 Proteomic 
Analyzer (Framingham, MA). For sequence confirmation, 50 pmol of each 
QconCAT was digested for 15 h at 37 °C with trypsin (50:1, mass ratio) in 25 
mmol/L NH4HCO3. Tryptic peptides were mixed with α-cyano-4-hydroxycinnamic 
acid matrix and analyzed by reflector mode and all expected peptides were 
observed. To determine level of 15N incorporation, peptide spectra were acquired 
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in reflector mode which provided isotopic peaks used to calculate percent 15N 
with Isotopic Enrichment Calculator [73]. Representative short and long peptides 
were chosen for each QconCAT to determine percent 15N (Figure 3.2). HDAC6 
full-length protein was used as standard protein for calibration curves and lower 
limit of quantification (LLOQ) of HDAC6 peptides present in QconCAT#2. 
3.2.2 Human Tissues 
Frozen frontal cortex was obtained from the Washington University School 
of Medicine Alzheimer’s Disease Research Center (St. Louis, MO). Eyes were 
acquired, characterized and dissected as described [94] at Case Western 
Reserve University (Cleveland, OH). Information regarding the acquisition and 
approval of human tissues is provided in Appendix A1.3 and demographic 
information of the de-identified donors is summarized in Table 3.4. 
3.2.3 Human Frontal Cortex Processing 
Minced frontal cortex tissue was homogenized in 25 mmol/L NH4HCO3 by 
sonication at 30 W using five 10 s continuous cycles (Sonicator 3000, Misonix 
Inc., Farmingdale, NY). Homogenates were centrifuged for 5 min at 2,000 g to 
remove debris. Resulting supernatant was measured for total protein 
concentration using detergent-compatible DC protein assay kit in the presence of 
1% SDS and bovine serum albumin as a standard. Homogenates were stored at 
-80 °C. Pools of 20 mg total protein were prepared from equal amounts of each 
AD (n=5) and normal (n=5) donors. Samples were centrifuged at 106,000 g for 1 
h at 4 °C. Supernatant, which contained soluble protein and HDAC, was 
supplemented with 10 pmol of each QconCAT , 20 mmol/L DTT , and 1% SDS.  
62 
 
Table 3.4 - Donor information. 
Donor ID Age (y) Gender Frontal cortex and retina status 
1 90 F frontal cortex, normal 
2 91.3 M frontal cortex, normal 
3 87 M frontal cortex, normal 
8 91.5 M frontal cortex, normal 
9 92.1 F frontal cortex, normal 
11 79 M frontal cortex, severe AD 
12 73.6 F frontal cortex, severe AD 
14 82 F frontal cortex, severe AD 
17 72 M frontal cortex, severe AD 
19 76 F frontal cortex, severe AD 
    
PM032 68 M neural retina, normal 
PM038 79 M neural retina, normal 
PM039 82 M neural retina, normal 
PM049 69 F neural retina, normal 
PM028 86 M neural retina, AMD-affected 
PM033 86 M neural retina, AMD-affected 
PM040 80 M neural retina, AMD-affected 
PM051 86 F neural retina, AMD-affected 
PM030 76 M neural retina, normal, history of AD 
PM041 77 F neural retina, normal, history of AD 
PM045 81 M neural retina, normal, history of AD 
 
Alzheimer’s disease (AD) in frontal cortex was evaluated by Clinical Dementia Rating 
with no dementia representing normal brain and severe dementia representing severe 
AD brain. Retina status was assessed by fellowship trained vitreo-retinal specialist and 
information about AD was in the clinical history provided by the eye bank. 
 
 
After 1 h incubation at room temperature to reduce cysteines, 55 mmol/L 
iodoacetamide was added and incubated for an additional 1 h to alkylate 
cysteines. Protein was isolated by chloroform/methanol precipitation. Protein 
pellets were sonicated in 1 mL 25 mmol/L NH4HCO3 and 0.1% RapiGest SF 
(Waters, Milford, MA) then treated in 25:1 mass ratio with trypsin overnight at 37 
°C. Following trypsinolysis, 0.5% TFA was added and incubated at 37 °C for 1 h 
to cleave acid-labile RapiGest. Samples were then centrifuged at 179,000 g for 
30 min at 4 °C to remove precipitated surfactant. Supernatants were dried using 
a Vacufuge (Eppendorf AG, Hamburg, Germany). 
63 
 
3.2.4 Human Retina Tissue Processing 
Three pools of post-mortem neural retina from human donors were 
prepared: normal retina from AD-unaffected (n=4) and affected (n=3) donors and 
retina from donors (n=4) with age-related macular degeneration (AMD). Pools 
with total protein amounts of 7.6 mg for normal retina, 8.8 mg for AMD, and 12.3 
mg for AD were supplemented with 5 pmol to 7 pmol of QconCAT standards. 
Samples were further processed similar to human frontal cortex. Protein pellets 
after chloroform/methanol precipitation were sonicated in 400 µL 25 mmol/L 
NH4HCO3 and 0.1% RapiGest then treated in 25:1 mass ratio with trypsin 
overnight at 37 °C. After trypsinolysis, 0.5% TFA was added and incubated at 37 
°C for 1 h. Samples were then centrifuged at 179,000 g for 30 min at 4 °C and 
supernatants were dried using a Vacufuge. Samples were reconstituted in 300 
µL 50% acetonitrile and centrifuged again at 65,000 g for 1 h at 4 °C to remove 
insoluble material before final drying in Vacufuge. 
3.2.5 Mice 
Animal handling procedures and approvals are provided in Appendix A1.4. 
5XFAD mice were obtained by crossing 5XFAD hemizygous males on B6SJL 
background (purchased from the Jackson laboratory) with wild type B6SJL 
females (also from The Jackson Laboratory). Only F1 males homozygous with 
respect to the transgene were used. Age-matched males on C57BL/6J 
background served as controls.  Mice were housed in the Animal Resource 
Center at Case Western Reserve University and maintained in a standard 12 h 
light/12 h dark cycle environment. Water and food were provided ab libitum. Mice 
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were sacrificed by cervical dislocation at the age of 4 months, and their brains 
were immediately isolated with the left hemisphere used for quantifications. 
3.2.6 Mouse Brain Processing 
Left hemispheres of the brain from 5XFAD male mice [22] (n=4) and age- 
and sex-matched wild type controls (n=2) were prepared similar to human frontal 
cortex and total protein was measured. Mouse brains were processed 
individually with no sample pooling. Five mg total protein of each mouse brain 
sample was supplemented with 5 pmol of QconCATs. Further sample processing 
was consistent with that of human brain. BLAST search of human-derived HDAC 
peptides in QconCATs was performed for mice and peptides present in mice 
were used in analysis of mouse brain samples. 
3.2.7 LC-MS/MS Analysis 
Dried peptides were reconstituted in 3% acetonitrile, 97% water, and 0.1% 
formic acid. Separation and MRM analysis was performed on an Agilent Zorbax 
Eclipse Plus C18 RRHD column (2.1 mm x 50 mm, 1.8 µm particle) coupled to 
Agilent 6490 Triple Quadrupole LC/MS system with iFunnel technology (Santa 
Clara, CA). Peptides were eluted over 30 min gradient from 15% to 35% 
acetonitrile containing 0.1% formic acid at a flow rate of 200 µL/min. Acquisition 
method used following parameters in positive mode: fragmentor 380 V, cell 
accelerator 4 V, electron multiplier 500 V, and capillary voltage 3500 V. Collision 
energy was optimized for each peptide using the default equation from Agilent, 
CE = 0.036 m / z  - 4.8 [95]. Dwell times were varied based on complexity of 
samples being analyzed and were in 80 ms to 120 ms range. 
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3.2.8 Data Analysis 
MRM transitions were predicted using OrgMassSpecR 
(http://orgmassspecr.r-forge.r-project.org/) and 2+ charge precursor ions were 
selected. Transitions were screened in digest of QconCATs to obtain the 3 or 4 
most intense transitions, which were further used for quantification (Figure 3.5). 
Relative signal ratios of transitions for quantification were similar in both the 
standard QconCAT digest and when QconCATs were added into tissue 
homogenates, indicating no obvious interference from biological matrices on the 
quantification using selected transitions. Ratio of peak areas for unlabeled 
biological peptides to fully-labeled 15N standard peptides was performed using 
MassHunter (Agilent) and pmol/mg concentrations were calculated based on 
known picomoles of standard and milligrams of total protein. Protein 
concentrations represent the mean ± standard deviation (SD) of transitions and 
peptides associated with each protein. Statistical significance of mean 
differences was determined by two-tailed Student’s t-test. 
3.3 Results and Discussion 
3.3.1 Design of QconCATs 
Tryptic peptides were predicted for all HDAC isoforms. Peptides that 
contained less than eight amino acids were removed to avoid small m/z values. 
Long peptides were excluded because they tend to have lower signal intensities 
and more charge states with electrospray ionization. In addition to size 
constraints, peptides containing methionine were avoided due to oxidation and 
cysteines were avoided due to potential disulfide bonds and oxidation, which 
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would interfere with quantification. Finally, sequences were screened with BLAST 
to ensure Q-peptides were unique in the human proteome. Q-peptides and their 
natural flanking sequences were assembled into QconCATs. The purpose of 
including natural flanking sequences is to reduce disparity in efficiency of tryptic 
digestion between endogenous protein and QconCAT.[58] Additionally, a His6-
tag was included on the C-terminal end, which ensured QconCATs purified by Ni-
NTA column would be full-length and not include truncated forms. An overview of 
design and expression is shown in Figure 3.1 and QconCAT sequences are 
presented in Tables 3.1, 3.2, and 3.3.  
3.3.2 Characterization of 15N QconCAT Internal Standard 
Purity of QconCATs was estimated by SDS-PAGE (Figure 3.2A) and 
ImageJ software to be nearly 100% for QconCAT#1, ≥95% for QconCAT#2, and 
≥97% for QconCAT#3. No correction for protein concentration was made for 
analysis. Intact mass of each QconCAT was consistent with expected mass, 
indicating full-length expression of protein. Figure 3.2B shows a representative 
spectrum and deconvolution for QconCAT#1. Deconvoluted mass for 
QconCAT#1 was 46126.7 (46125.6 Da theoretical), QconCAT#2 was 48931.2 





Table 3.5 - Transitions used for quantification. 
    Precursor 
(m/z) 
Product Ions (m/z) 
Isoform Peptide Species 
 
1 2 3 
HDAC1,2 YGEYFPGTGDLR human/mouse L 687.8 715.4 (y7) 862.4 (y8) 1025.5 (y9) 
   
H 695.3 725.3 (y7) 873.4 (y8) 1037.5 (y9) 
HDAC3 YTGASLQGATQLNNK human/mouse L 783.4 845.4 (y8) 973.5 (y9) 1173.6 (y11) 
   
H 793.4 857.4 (y8) 987.5 (y9) 1189.6 (y11) 
HDAC4 ESAVASTEVK human/mouse L 510.8 563.3 (y5) 634.3 (y6) 733.4 (y7) 
   
H 516.2 569.3 (y5) 641.3 (y6) 741.4 (y7) 
 
DQPVELLNPAR human/mouse L 626.3 683.4 (y6) 812.5 (y7) 1008.6 (y9) 
   
H 634.3 693.4 (y6) 823.4 (y7) 1021.5 (y9) 
HDAC5 LSTQQEAER human/mouse L 510.8 632.3 (y5) 760.4 (y6) 861.4 (y7) 
   
H 531.3 641.3 (y5) 771.3 (y6) 873.4 (y7) 
 
GALVGSVDPTLR human L 592.8 601.3 (y5) 787.4 (y7) 844.5 (y8) 
   
H 600.3 609.3 (y5) 797.4 (y7) 855.4 (y8) 
HDAC6 EQLIQEGLLDR human/mouse L 657.4 702.4 (y6) 830.4 (y7) 943.5 (y8) 
   
H 665.3 711.4 (y6) 841.4 (y7) 955.5 (y8) 
 
LEELGLAGR human L 479.3 586.4 (y6) 715.4 (y7) 844.5 (y8) 
   
H 485.3 595.3 (y6) 725.4 (y7) 855.4 (y8) 
HDAC7 TLEPLETEGATR human L 658.8 763.4 (y7) 876.4 (y8) 1102.5 (y10) 
   
H 666.3 773.3 (y7) 887.4 (y8) 1115.5 (y10) 
 
Transitions are listed for both unlabeled, light (L) and fully 15N-labeled, heavy (H) 
peptides. All precursor ions were +2 charge and product ions were +1 charge. 






Figure 3.2 - Purity and size of QconCATs. 
(A) Purified QconCATs (30 pmol of QconCAT#1, 22 pmol of QconCAT#2, and 25 pmol 
of QconCAT#3) were separated on 10% SDS-PAGE and ImageJ software was used for 
estimation of purity. Purity was nearly 100% for QconCAT#1, ≥95% for QconCAT#2, and 
≥97% for QconCAT#3. Protein concentrations were determined by DC Protein Assay. 
(B) Charge state masses were collected for all QconCATs (representative spectrum of 
QconCAT#1 shown) with an Agilent 6550 QTOF and deconvoluted with MagTran 1.0 
(insert) to confirm protein mass was congruous with expected mass based on sequence. 
Observed mass of QconCAT#1 was 46126.7 Da (46125.6 Da theoretical), QconCAT#2 
was 48931.2 Da (48929.7 Da theoretical), and QconCAT#3 was 43167.8 Da (43166.6 
Da theoretical).  
69 
 
15N isotope incorporation (Figure 3.3) was determined using a relatively short and 
long peptide for each QconCAT and both peptide lengths yielded consistent 
results. Incorporation was 99.3% for QconCAT#1, 99.3% for QconCAT#2, and 
99.4% for QconCAT#3. These values were accepted as complete labeling and 
no correction was applied to data. Calibration curves were performed using 
variable amounts of unlabeled HDAC6 mixed with a fixed amount of 
QconCAT#2, which contained HDAC6 peptides. Calibration curves showed 
linearity of Q-peptides in the 0.125 pmol to 2.5 pmol HDAC6 range tested; Figure 
3.4 shows a representative calibration curve for peptide LEELGLAGR. Lower 
limit of quantification (LLOQ) was defined as the lowest point of calibration curve 
that could be measured with a coefficient of variance less than 20%. LLOQ for 
HDAC6 peptide LEELGLAGR was 0.05 pmol in mixture of HDAC6 standard and 
QconCAT#2 internal standard. A representative chromatogram and spectrum of 
a Q-peptide is shown in Figure 3.5. 
3.3.3 Human Frontal Cortex 
The outermost portion, or cortex, of the frontal lobe was used for sample 
preparation. Cortex is commonly referred to as gray matter and consists primarily 
of neural cell bodies with few myelinated axons. Measurements in frontal cortex 
present a challenge due to the high lipid content, approximately 40% of dry 
weight [96]; therefore sample processing is important. Two methods of 
fractionation were used to reduce sample complexity while maintaining the same 





Figure 3.3 - 15N incorporation in QconCATs. 
MALDI spectra of QconCAT peptides were used to calculate 15N incorporation with 
Isotopic Enrichment Calculator (www.nist.gov/mml/analytical/organic/isoenrichcalc.cfm). 
Incorporation of 15N was determined to be 99.3% for QconCAT#1, 99.3% for 








Figure 3.4 - Calibration curves. 
Calibration for quantification of peptide LEELGLAGR from HDAC6 standard using 15N-
labeled peptide from QconCAT#2 as internal standard. Area ratio of 14N-LEELGLAGR to 
15N-LEELGLAGR for each of the three transitions for quantification was plotted versus 
pmol of HDAC6 standard. Individual transitions shown are (t1) 479.3/586.4 and 
485.3/595.3, (t2) 479.3/715.4 and 485.3/725.4, (t3) 479.3/586.4 and 485.3/595.3. Three 
replicates for each were collected and presented as mean ± SD. Consensus for t1-t3 is 





Figure 3.5 - Representative chromatogram and spectrum. 
Transitions for HDAC1,2 peptide YGEYFPGTGDLR in 5XFAD mouse brain hemisphere 
are shown as a (A) chromatogram and (B) spectrum. Chromatogram peaks of 
transitions are representative of data for other peptides in neural tissue. Peak areas 
were used for quantification.  
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High speed centrifugation at 106,000 g was performed which separated 
membrane associated proteins and some lipids from soluble proteins and 
HDACs. Additionally, chloroform/methanol precipitation was performed which 
removed SDS, by-products of cysteine alkylation, remaining lipids, and salts. 
These two fractionation steps are important for the success of the mass 
spectrometry method of quantification, improving chromatographic performance 
and reducing ion suppression effects. 
Measurements were performed on pooled samples from AD (n=5) and 
normal (n=5) human frontal cortex. The purpose of using pooled tissue samples 
is to minimize the effects of donor-to-donor variation while maintaining the 
biological variation between donor groups, allowing for evaluation of substantive 
characteristics of the donor population. This research functions as a feasibility 
study, demonstrating the applicability of QconCAT technology with MRM MS to 
conduct protein quantification in a complex biological matrix, such as brain. While 
our study findings are based on pools from five donors in each sample group, our 
method can easily be applied to a large number of individual donor samples, if a 
larger number of samples are available. HDAC isoforms detected in human 
frontal cortex are summarized in Table 3.6. Out of the 11 isoforms, we detected 
HDAC1,2, HDAC5, and HDAC6 only. Other HDAC isoforms are either (i) not 
significantly expressed in human frontal cortex or (ii) expressed at levels in 
human frontal cortex that are below the limit of quantification of our MRM assay, 
which is approximately 5 fmol/mg total protein. Concentration of HDAC1,2 
decreased 32% from 1.10 pmol/mg in control to 0.746 pmol/mg in AD. 
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Table 3.6 – Summary of human frontal cortex HDAC concentrations. 
 




HDAC1,2 1.10 ± 0.14 
 
0.746 ± 0.071c 
HDAC5 0.083 ± 0.016 
 
0.122 ± 0.025b 
HDAC6 0.106 ± 0.015 
 
0.139 ± 0.015c 
 
aMeasurements were performed on supernatant of frontal cortex from age-matched 
control (n=5) and severe AD (n=5) human donor pools (Table 3.4) supplemented with 
QconCAT standard after high-speed centrifugation. Concentrations were calculated for 
three biological replicates and with three transitions per Q-peptide. Q-peptide transitions 




HDAC1,2 measurement was based on a peptide in both isoforms because 
HDAC1 and HDAC2 have similar sequences and unique peptides included in 
QconCATs did not produce signals sufficient for detection or quantification. 
Therefore, we were not able to ascertain whether both HDAC1 and HDAC2 
decreased but were able to determine the sum of their concentrations decreased 
in AD. HDAC5 and HDAC6 both showed an increasing trend of 47% and 31%, 
respectively. Work by others has shown that HDAC5 is correlated to repression 
of angiogenesis [97] and HDAC6 is correlated with protein aggregation [81,98,99] 
in mouse models. Conversely, decreases in HDAC5 can impair memory, which is 
a function of the hippocampus and temporal lobe, suggesting HDAC isoforms 
may vary by brain regions. 
 Immunohistochemical staining of cerebral cortex in The Human Protein 
Atlas (www.proteinatlas.org) shows HDAC2 is highly abundant, and when 
combined with less expressed HDAC1, they would be among the most abundant 
of the HDACs. They report HDAC5 is present at medium levels and HDAC6 at 
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low levels. While our concentrations of HDAC5 and HDAC6 are within a similar 
range and in a specific portion of the cerebral cortex, called the frontal cortex, the 
qualitative levels on these HDACs available in The Human Protein Atlas are 
similar to our profile. Additionally, quantitative polymerase chain reaction assays 
by Jakovceoski et al. have shown transcript levels of HDAC1, 2, 5, and 6 are 
nearly identical in frontal cortex [100], which is consistent with our findings given 
that HDAC1 and 2 are combined. HDAC6 has been shown to increase in AD 
brain [101], as we have shown. However, it has been reported that HDAC2 
increases and HDAC1 remains normal in AD brain and cortex [102,103], counter 
to our observed trends. 
3.3.4 Human Retina 
Neural retina is a specialized extension of the central nervous system 
(CNS) connected to the occipital lobe of the brain. We selected neural retina to 
test our protocol of HDAC quantification in a different biological matrix and to 
gain insight into AD changes in other functionalized portions of the CNS. Sample 
processing procedures for frontal cortex were also applied to retina, enabling 
quantification of HDACs in this tissue (Table 3.7). Similarity in HDAC coverage 
acquired in frontal cortex demonstrates this procedure is also appropriate for 
neural retinal tissue matrix. Retina samples were obtained from AD-affected and 
AMD donors to evaluate changes in HDACs in these disease states. AMD retina 
was included because it is another degenerative disease associated with aging 
and has several clinical similarities with AD, including amyloid deposition and 
stress stimuli [93,104,105]. HDAC concentrations in retina are summarized in 
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Table 3.7. A decrease in concentration was observed for all detected HDAC 
isoforms in normal retina from AD-affected donors compared to normal retina 
from AD-unaffected donors. HDAC1,2 decreased similarly in both AD-affected 
tissue types of retina and frontal cortex and showed a slight decrease in AMD 
retina. HDAC5 and HDAC6 showed a decrease in AMD retina and a greater 
decrease in retina from AD-affected donors, counter to the increasing trend 
observed in frontal cortex. HDAC7 did not appear to change in concentration in 
AMD retina but was nearly reduced in half in retina from AD-affected donors. 
In addition to trends in concentration of retinal HDACs and their 
comparison to those in frontal cortex in disease state, overall profile of HDAC 
isoforms was also different in retina and frontal cortex. HDAC1,2 and HDAC5 
had similar levels of concentration in both frontal cortex and retina tissues while 
HDAC6 in retina was approximately five-fold greater than the concentration in 
control frontal cortex. 
 
Table 3.7 - HDAC concentrations in human neural retina. 
 






HDAC1,2 1.63 ± 0.12 
 
0.743 ± 0.065c 
 
1.14 ± 0.19c 
HDAC5 0.106 ± 0.014 
 
0.0393 ± 0.0077c 
 
0.074 ± 0.017b 
HDAC6 0.558 ± 0.081 
 
0.298 ± 0.062c 
 
0.415 ± 0.032c 
HDAC7 0.078 ± 0.020 
 
0.0251 ± 0.0068c 
 
0.069 ± 0.017 
 
aMeasurements were performed on supernatant of retina from control (n=4), AD-affected 
(n=3), and AMD (n=4) human donor pools (Table 3.4) supplemented with QconCAT 
standards after high-speed centrifugation. Concentrations were calculated for three 
experimental replicates and with three transitions per Q-peptide. Q-peptide transitions 
are summarized in Table 3.5. Data presented as mean ± SD. b, p < 0.01; c, p < 0.001.  
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Additionally, HDAC 7 was detected in retina in concentrations comparable 
to HDAC5 in retina but was not detected in frontal cortex.  Disparity in changes in 
retina from those in frontal cortex is an interesting pathological phenomenon that 
may suggest importance of HDAC isoforms and their respective roles in 
specialized tissues. HDAC1, 3, and 6 have been shown by Western blot to 
decrease in concentration in retina as it ages, while HDAC2 and 5 remain 
unchanged [106]. We also observed a decrease in HDAC1,2 and in HDAC6 in 
disease-affected retina, perhaps indicative of their decreased abundance in 
aging tissue. 
3.3.5 Mouse Brain 
Whole hemisphere of brain was analyzed for several reasons. Firstly, 
whole hemisphere of mouse brain was homogenized during sample preparation 
and HDAC concentrations reflect inclusive averages for the entire brain rather 
than a specific, functionalized portion of human brain, such as frontal cortex. 
Secondly, tissue matrix varies from human frontal cortex, which mainly contains 
only gray matter, to the brain hemisphere of mice, which includes white matter 
rich in myelinated axons. Lipids are a concern in brain tissue analysis and whole 
brain tissue contains more lipids than gray matter of frontal cortex due to the 
abundance of myelin, which is 80% lipid by dry weight [96]. Thirdly, and perhaps 
most important for AD pathology, HDAC profiles in mouse models may be 
compared to that of human frontal cortex. There are two main points to consider 
in comparing mouse and human HDAC profiles for AD: species variation and 
familial versus sporadic AD. While the eleven main isoforms of HDACs are 
78 
 
present in both mice and humans, there are some differences in the amino acid 
sequences that had to be taken into account. Accordingly for mouse sample 
analysis, BLAST was used to refine human peptides present in expressed 
QconCATs to those for both human and mouse isoforms, approximately half of 
total human peptides. Thus, not all peptides measured in human were used to 
obtain HDAC concentrations in mice. Additionally, HDAC isoform concentrations 
could be dictated by levels of HDAC regulation in mice different from that in 
humans. Another important caveat to using animal models for AD research is 
that mice may only be produced as models of familial AD via known mutations. 
The vast majority of AD cases in humans are considered sporadic AD and 
cannot be predicted. While clinical indicators of AD, such as amyloid 
aggregation, may be present in both sporadic and familial AD, pathogenesis may 
vary. In this study, 5XFAD transgenic mouse models of rapid brain amyloidosis 
were used. 5XFAD mice overexpress two mutant human proteins: presenilin 1 
with familial AD (FAD) mutations M146L and L286V and β-amyloid precursor 
protein (APP695) with Swedish (K670N, M671L), Florida (I716V), and London 
(V717I) FAD mutations. Mixed wild type B6SJLF1/J mice are used for the 
production of 5XFAD transgenic mice and therefore provide an appropriate 
background strain of wild-type mice, which were used as our control. 
HDAC isoform concentrations in both control and 5XFAD mice are 
summarized in Table 3.8. HDAC1,2 had no change in 5XFAD mice but 
decreased by 1.5-fold in AD human frontal cortex (Table 3.6). Since HDAC1,2 
measurements were based on a conserved peptide, we were unable to 
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determine the contribution of isoforms HDAC1 and HDAC2 to the reported 
measurements. HDAC3 had a slight increase of 50%, HDAC4 also increased by 
63%, and HDAC5 and HDAC6 did not show significant change in 5XFAD mouse 
model. Of the HDAC isoforms reported for both mouse and human profiles, 
HDAC1,2 was most abundant in both. However, HDAC3 and HDAC4 were within 
the concentration range of other isoforms in HDAC profile in mouse model yet 
not detected in human. Inconsistency in observed HDAC profiles of human and 
mouse brains may be for several reasons, such as differences in expression of 
HDACs between species, differences in functionalization of frontal cortex to 
whole brain hemisphere, and post-translational modification of peptides used for 
quantification. Additionally, due to sampling limitations, small portions of frontal 
cortex tissue were excised from human donors at random by support 
pathologists. It may be possible that patterning of HDACs varies across the 
frontal cortex region of the brain. While our pilot study highlights specific HDAC 
changes, future studies using our MRM assay could be performed on many sites 
across a particular donor to address variability in HDAC concentrations within 
frontal cortex. Mouse models allow for knockout and overexpression studies for 
disease pathology but our work suggests HDAC findings in mouse models 
should not be over interpreted without evaluation of human tissue. 
HDAC profiles in mouse brain were evaluated by Broide et al. [89] using in 
situ hybridization and they found that HDAC3, 4, and 5 were close in abundance 
with HDAC6 being less abundant and the sum of HDAC1 and 2 being more 




Table 3.8 - HDAC concentrations in whole hemisphere of mouse brain. 
 




HDAC1,2 1.010 ± 0.074 
 
1.02 ± 0.23 
HDAC3 0.131 ± 0.010 
 
0.196 ± 0.024b 
HDAC4 0.230 ± 0.029 
 
0.375 ± 0.023c 
HDAC5 0.154 ± 0.015 
 
0.143 ± 0.023 
HDAC6 0.0149 ± 0.0039 
 
0.0171 ± 0.0022 
 
aMeasurements were performed on supernatants of whole left hemispheres of mouse 
brains from 5XFAD (n=4) and wild type (n=2) mice supplemented with QconCAT 
standards after high-speed centrifugation. Three transitions per Q-peptide were used to 
calculate concentration for each mouse. Wild type (n=2) and 5XFAD (n=4) mice 
concentrations were averaged and data is presented as mean ± SD of each sample 
group. Q-peptide transitions are summarized in Supporting Information S5 Table. b, p < 
0.05; c, p < 0.01. 
 
 
autoradiography with a radioactive isotopologue to an inhibitor of HDAC1-3 and 8 
to measure pmol/mg concentrations ex vivo in mouse brain [107]. They were 
unable to detect HDAC8, as we were unable to, which was confirmed by Western 
blot. They reported the sum of HDAC1-3 concentrations to be 12.9 pmol/mg 
within mouse brain, more than our measurement of 1.14 pmol/mg. While their 
method was able to provide pmol/mg concentrations, this was based on binding 
to an inhibitor shared between multiple HDACs and individual HDAC 
measurements would have to be derived by using Western blot intensities of 
HDAC1, 2, and 3 performed in parallel to account for contribution of each HDAC 
isoform bound to the labeled inhibitor. 
Measurements for HDAC5 and 6 in human tissues and HDAC4 in mouse 
tissue were performed using two peptides for each isoform (Table 3.5). When 
measured individually, peptides were in close agreement with the other 
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respective peptide for the isoform (Table 3.9). This demonstrates that the 
peptide-to-peptide variability in measurement was not statistically significant 
using the MRM assay with QconCATs as internal standards. 
 
 
Table 3.9 - Comparison of individual Q-peptide and protein measurements. 
Mouse brain (control) pmol/mg 
ESAVASTEVK 0.229 ± 0.028 
DQPVELLNPAR 0.231 ± 0.034 
HDAC4 (total) 0.230 ± 0.029 
  
Human frontal cortex (control) pmol/mg 
GALVGSVDPTLR 0.085 ± 0.020 
LSTQQEAER 0.080 ± 0.010 
HDAC5 (total) 0.083 ± 0.016 
  
EQLIQEGLLDR 0.102 ± 0.010 
LEELGLAGR 0.112 ± 0.018 
HDAC6 (total) 0.106 ± 0.015 
 
Three transitions for each Q-peptide (Supporting Information S5 Table) were used for 
measurements in biological replicate samples of control human frontal cortex (n=5) and 
whole hemispheres of control mice (n=2). For HDACs 4, 5, and 6, two Q-peptides were 
used for quantification of each protein. Concentrations of mean ± SD for individual 
peptides are presented for comparison to mean ± SD for protein measurements, which 
include a total of both peptides (bold). Student t-test was performed and concentrations 
of peptides for the same protein were not statistically different in comparison to each 






Concentrations of several HDAC isoforms were obtained in three different 
tissues: human frontal cortex, human retina, and whole mouse brain. We 
demonstrated that our method of protein quantification is suitable in different 
types of tissues, particularly in challenging matrices with high lipid content. In 
human frontal cortex, observed HDAC isoforms had different changes in control 
to AD with HDAC1,2 decreasing, HDAC5 increasing, and HDAC6 having 
negligible change in concentration. In human retina, reduction in concentration of 
detected HDACs was observed in both AMD retina and retina from AD donors in 
comparison to control retina. Mouse brain depicted a slightly different HDAC 
profile from humans with variance in overall HDAC3 and HDAC4 abundance 
being greater in mouse. Additionally, HDAC1,2 concentrations in AD-affected 
donors decreased compared to control in both human frontal cortex and retina 
but showed no change in mouse hemisphere. Mouse models are widely used for 
neurodegenerative research and our data indicates some disparity in HDAC 
profiles and changes in disease state compared to human frontal cortex tissue. 
However, limitations in Q-peptides suitable for MRM did restrict our HDAC 
profile in tissues examined. Many HDAC isoforms have similar sequences and 
therefore selecting unique sequences that meet MRM criteria, such as length and 
no post-translational modifications, restricts availability of Q-peptides. 
Furthermore, some peptides do not perform well either in ionization efficiency or 
reproducibility of transitions. Once unsuitable peptides are excluded, HDAC 
isoform profiles were further restricted to isoforms that can be observed in 
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biological sample. Some HDACs may be present at very low levels precluding 
their detection via MRM and may require more sensitive approaches, such as an 
enzyme-linked immunosorbent assay (ELISA). While the QconCAT MRM method 
may have shortcomings, it is able to multiplex protein quantification, reduce 
analysis time, and accounts for loss during sample processing compared to 
synthetic labeled peptides and ELISA [60]. 
Our feasibility study demonstrates the value of MRM mass spectrometry 
and QconCAT technology to perform multiplexed, quantitative measurements of 
HDAC isoforms in various tissues. Moreover, our measurements show that 
changes in concentrations of HDACs have different trends in frontal cortex and 
neural retina in AD and that mouse hemisphere and human frontal cortex HDAC 
profiles differ. This method may be applied to other tissues and disease 
conditions to obtain concentrations of HDAC isoforms, a practical and useful tool 





Chapter 4: Phosphorylation of Histone H3 Ser57 and Thr58 
This chapter contains published material [54]. 
4.1 Introduction 
One common PTM on histones is phosphorylation of serine (Sp) and 
threonine (Tp) residues, which has been linked to activation and repression of 
genes based on site of modification and condition of cells [41–43]. Serine 
phosphoacceptor sites are found on the tail regions of all core histones [108]. 
Phosphorylation of S10 on histone H3 (H3S10p) has been extensively studied for 
its roles in condensation of chromatin during mitosis [42,43] and to a lesser 
extent in neurodegenerative disorders, such as AD [109]. While many types of 
PTMs on histone tails have been associated with disease, little information exists 
on PTMs in the core region of histones. It is suggested that phosphorylation of 
H3 may be particularly meaningful compared to other core histones [41,110]. 
Specifically in the core region of H3, there are several potential threonine and 
serine phosphorylation sites, but exploration of their significance has been 
minimal. H3T45p is directly correlated with apoptosis [111], H3T80p is increased 
in mitosis [112], and H3T118p destabilizes the nucleosome [113]. However, little 
is known about H3S57 and H3T58 phosphorylation roles in normal biological 
functions and there is no information to date describing changes in these 
phosphorylation sites in AD brain. H3S57p has been detected in mammalian 
cells and may have implications in response to DNA damage based on studies in 
yeast [114]. H3T58p has not been previously characterized. Additionally, we 
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investigated in silico potential phosphorylation sites on the surface of the 
nucleosome which could be easily accessible to kinases and phosphatases and 
found that S57 and T58 are located on the surface. Specifically, these adjacent 
residues occur in an accessible turn of a helix-turn-helix motif of H3 in close 
proximity to DNA, which suggests these sites may engage in regulatory 
phosphorylation and supports investigation into these sites in brain and AD 
pathology. 
Initially, we screened human frontal cortex for phosphorylation but were 
unable to detect any phosphorylation in the human tissue. We believed this is 
due to loss of phosphorylation in the time frame between the death of the donor 
and when the brain tissue was frozen, referred to as the post-mortem interval 
(PMI). PMI for most of our brain tissue from human donors ranged from 6 to 10 h. 
During the PMI, phosphatases are still active and able to remove phosphoryl 
groups from histones, additionally, phosphorylation is a very labile PTM and 
these effects likely degraded the histone phosphorylation. We instead chose to 
use the 5XFAD mouse model of rapid amyloid deposition as our subject for 
investigation of H3 phosphorylation at S57 and T58 sites because the PMI for 
mice was within minutes. 
5XFAD mice were also treated with a low dose of efavirenz (EFV), an 
FDA-approved reverse transcriptase inhibitor used for the treatment of HIV. At 
clinical levels for HIV treatment, EFV has been shown to increase expression of 
β-secretase, an enzyme responsible for processing amyloid precursor protein 
(APP), and increase levels of soluble Aβ in murine N2a cells expressing the 
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Swedish APP mutation [115]. At levels a hundred-fold lower than used for HIV, 
EFV stimulates activity of cytochrome P450 CYP46A1, a brain-specific 
cholesterol 24-hydroxylase, which increases cholesterol turnover in mouse brain 
[116]. Elevated cerebral activity of cytochrome P450 CYP46A1 allows for 
clearance of cholesterol from the brain and is shown to ameliorate cognitive 
impairment and amyloid pathology in mouse models of neurodegeneration 
[117,118]. Moreover, cholesterol metabolism is linked to AD with 
hypercholesterolemia increasing Aβ plaques and hypocholesterolemia reducing 
Aβ plaques in brain [119,120]. Other neuroprotective effects may occur with low 
dose EFV administration that may affect epigenetic indicators, namely PTMs of 
histones. It was therefore prudent to measure changes in histone H3 S57 and 
H3T58 phosphorylation for EFV-associated effects. 
This study shows that phosphorylation of both S57 and T58 on histone H3 
is lower in 5XFAD models of amyloid deposition in comparison to wild type 
controls. Since changes in PTMs of histones are established to influence genetic 
expression, our measurements of specific histone H3 residues S57 and T58 may 
provide insight into the epigenetic blockade phenomenon in the pathology of 
neurodegeneration. While EFV treatment did not have observable effects, this 
may indicate either: (i) the neuroprotective mechanism of EFV is unrelated to 
S57 and T58 phosphorylation; (ii) the proposed therapeutic dosage of EFV was 







All animal-handling procedures and approvals are provided in Appendix 
A1.4. 5XFAD mice [22] were maintained by crossing 5XFAD hemizygous males 
on B6SJL background (The Jackson Laboratory) with B6SJL females (The 
Jackson Laboratory, stock 100012). Only F1 males homozygous with respect to 
the transgene were used. Wild type C57BL/6J mice (The Jackson Laboratory, 
stock 000664), a common laboratory strain that does not develop amyloid 
plaques, and the progenitor strain used to make transgenic 5XFAD, were used 
as a control. Mice were housed in the Animal Resource Center at Case Western 
Reserve University and maintained in a standard 12 h light/12 h dark cycle 
environment. Water and food were provided ab libitum. 5XFAD male mice (n=3) 
and C57BL/6J age- and sex-matched wild type controls (n=3) were sacrificed at 
3 months of age to assess the differences. Additional age- and sex-matched 
5XFAD mice were maintained with EFV treatment (n=3) and without treatment 
(n=3) for a three month period. For EFV treated mice, administration of EFV was 
commenced after a one week period of acclimation. EFV was administered 
through drinking water at a concentration of 1.68 mg/liter, which was provided ad 
libitum. Daily dose of EFV during the 3-month treatment period was 0.22 mg/kg. 
4.2.2 Whole Mouse Brain Processing 
Hemispheres of brains were harvested and flash-frozen in liquid nitrogen 
for storage at -80 °C. Left hemispheres of the brain were finely minced with a 
scalpel blade and homogenized in 25 mmol/L NH4HCO3 by sonication at 30 W 
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using five, 10 second continuous cycles (Sonicator 3000, Misonix Inc., 
Farmingdale, NY). Total protein concentration of the homogenate was measured 
using a DC protein assay kit in the presence of 1% sodium dodecyl sulfate (SDS) 
with bovine serum albumin as the standard. Homogenates were aliquoted and 
stored at -80 °C. Samples of 3 mg total protein were supplemented with 12 pmol 
APP QconCAT standard [70] and treated with 20 mmol/L dithiothreitol (DTT) and 
1% SDS. After 1 h incubation at room temperature to reduce cysteines, 55 
mmol/L iodoacetamide was added and incubated an additional 1 h to alkylate 
cysteines. Chloroform/methanol precipitation was used to isolate proteins. 
Protein pellets were then sonicated in 1 mL 25 mmol/L NH4HCO3/0.1% RapiGest 
SF surfactant and treated with trypsin at 25:1 protein:trypsin mass ratio overnight 
at 37 °C. After trypsinolysis, 0.5% trifluoroacetic acid (TFA) was added and 
incubated at 37 °C for 1 h to cleave acid-labile RapiGest SF surfactant, which 
was subsequently removed by centrifugation at 179,000 g for 30 min at 4 °C. 
Supernatants were dried in an Eppendorf AG Vacufuge (Hamburg, Germany), 
yielding final peptides for analysis. 
4.2.3 LC-MS/MS Analysis 
Dried peptides were reconstituted in 3% acetonitrile, 97% water, and 0.1% 
formic acid. Separation was performed on an Agilent Zorbax Eclipse Plus C18 
RRHD column (2.1 mm x 50 mm, 1.8 µm particle) and MRM analysis was 
performed on an Agilent 6490 iFunnel Triple Quadrupole LC/MS system (Santa 
Clara, CA). Peptides were eluted at a flow rate of 200 µL/min using the following 
gradient of solvent B in solvent A: 3% B for 3 min, 3% to 30% B in 32 min, 30% 
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to 50% B in 5 min, and 50% to 3% B in 3 min. Solvent A was water containing 
0.1% formic acid and solvent B was acetonitrile containing 0.1% formic acid. The 
acquisition method used the following parameters in positive mode: fragmentor 
380 V, collision energy 20 V, dwell time 100 ms, cell accelerator 4 V, electron 
multiplier 500 V, and capillary voltage 3500 V. MRM transitions for 2+ charge 
precursor ions and 1+ charge product ions were predicted using PinPoint 
software (Thermo Fisher Scientific, Waltham, MA). 
4.2.4 Data Ana ysis for APP and Aβ 
Quantification of total APP and Aβ in mouse brain samples, using MRM 
with QconCAT as an internal standard [70], was performed to confirm that the 
5XFAD model of amyloid pathogenesis produced significant Aβ in comparison to 
the control. The QconCAT standard used contained peptides for both APP and 
Aβ [70] and was supplemented into homogenates prior to processing to increase 
precision and accuracy of measurements. Based on sequence specificity and 
measured intensity, a single peptide, LVFFAEDVGSNK, was selected from Aβ 
and two peptides, VESLEQEAANER and AVIQHFQEK, were selected to 
measure total APP. APP is a large transmembrane protein that undergoes 
processing to release the fragment Aβ. Therefore, the Aβ amino acid sequence 
is part of the APP protein. Measurements for Aβ are inclusive of the Aβ fragment 
and unprocessed APP, which still contains Aβ. These peptides were included in 
a stable isotope labeled QconCAT standard, as previously described [70], which 
was supplemented into samples. Quantification of APP and Aβ was performed by 
calculating the ratio of peak areas for unlabeled biological peptides to labeled 
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standard peptides using MassHunter software (Agilent) multiplying by the ratio of 
known picomoles of standard to milligrams of total protein. Protein concentrations 
are presented as pmol/mg and represent the mean ± standard deviation (SD) of 
peptide transitions associated with each protein. Statistical significance of mean 
differences was calculated using Student’s two-tailed t-test and was considered 
significant if p ≤ 0.05. Transitions used for quantification of APP and Aβ are 
presented in Table 4.1. 
4.2.5 Data Analysis for Phosphorylation 
All selected MRM transitions were used to confirm the identity of each 
peptide for each LC-MS analysis and a representative transition for each peptide 
was chosen for quantification (Table 4.2). Quantitative transitions were stable in 
replicate injections and produced signal reasonable for comparison to other 
peptides. Additionally, the ratio of quantitative transitions to remaining transitions 
for each precursor was consistent across biological samples, indicating 
quantitative transitions were not biased. Peak areas of quantitative transitions 
were calculated using MassHunter software from Agilent. Peak areas of 
phosphorylated peptides were normalized to peak area of calibrant peptide, 
EIAQDFK. Triplicate biological replicates, each with triplicate analytical 
replicates, produced n=9 normalized ratios, which were averaged together and 
presented as mean ± standard deviation. Statistical significance of mean 
differences was calculated using Student’s two-tailed t-test. An example of 
calculations from raw integrated peak areas to normalized and averaged values 







Table 4.1 - MRM transitions for quantification o  APP and Aβ. 
   Precursor 
(m/z) 
Product Ions (m/z) 
Isoform Peptide 
 
1 2 3 4 
Aβ LVFFAEDVGSNK L 663.3 748.3 (y7) 819.4 (y8) 966.5 (y9) 1113.5 (y10) 
  
H 667.3 756.4 (y7) 827.4 (y8) 974.5 (y9) 1121.5 (y10) 
APP VESLEQEAANER L 687.8 689.3 (y6) 817.4 (y7) 946.4 (y8) 1146.5 (y10) 
  
H 692.8 699.3 (y6) 827.4 (y7) 956.4 (y8) 1156.5 (y10) 
APP AVIQHFQEK L 550.3 688.3 (y5) 816.4 (y6) 929.5 (y7)  
  
H 554.3 696.4 (y5) 824.4 (y6) 937.5 (y7)  
 
Two peptides were selected to represent total amyloid precursor protein (APP) and a 
single peptide for amyloid beta (Aβ). Measurements using peptide for Aβ are a sum of 
all Aβ-containing proteins, including unprocessed APP and various processed forms of 
Aβ. Unlabeled, light (L) transitions were used to measure protein in brain, labeled, heavy 













EIAQDFK 425.72 409.21 y3 
EIAQDFK 425.72 537.27 y4 
EIAQDFK 425.72 608.30 y5 
EIAQDFK 425.72 721.39 y6 
SpTELLIR and STpELLIR 456.23 407.25 neutral loss 
SpTELLIR and STpELLIR 456.23 401.29 y3 
SpTELLIR and STpELLIR 456.23 514.37 y4 
SpTELLIR and STpELLIR 456.23 643.41 y5 
STpELLIR 456.23 824.43 y6 
SpTELLIR 456.23 744.46 y6 
SpTpELLIR 496.22 447.23 neutral loss 
SpTpELLIR 496.22 401.29 y3 
SpTpELLIR 496.22 514.37 y4 
SpTpELLIR 496.22 643.41 y5 
SpTpELLIR 496.22 824.43 y6 
 
Phosphorylation (p) is indicated following the modified amino acid. All precursor ions 
were +2 charge and product ions were +1 charge. Specific ion (y-ion or neutral loss ion) 














Normalized to H3 
Sample 
 
Trial 1 Trial 2 Trial 3 
 
Trial 1 Trial 2 Trial 3 
Mixed WT A S57p 62949 49770 49050 
 
5.69 6.52 6.94 
 
T58p 9169 7010 6452 
 
0.83 0.92 0.91 
 
S57p/T58p 18585 13222 12205 
 
1.68 1.73 1.73 
 
H3 11072 7631 7065 
    
         Mixed WT B S57p 88595 115736 110106 
 
6.89 7.03 7.36 
 
T58p 11625 14957 15864 
 
0.90 0.91 1.06 
 
S57p/T58p 23837 29511 29437 
 
1.85 1.79 1.97 
 
H3 12863 16462 14955 
    
         Mixed WT C S57p 26263 48344 43994 
 
6.35 6.84 7.04 
 
T58p 4257 7240 6560 
 
1.03 1.02 1.05 
 
S57p/T58p 9974 18475 16279 
 
2.41 2.61 2.61 
 
H3 4137 7073 6245 
    
         5XFAD A S57p 62367 61164 56620 
 
3.86 4.01 3.98 
 
T58p 7513 8176 7302 
 
0.46 0.54 0.51 
 
S57p/T58p 19122 13566 15859 
 
1.18 0.89 1.12 
 
H3 16175 15241 14210 
    
         5XFAD B S57p 25894 16284 14155 
 
3.48 3.80 3.81 
 
T58p 3439 2203 1950 
 
0.46 0.51 0.53 
 
S57p/T58p 14015 7230 6099 
 
1.88 1.69 1.64 
 
H3 7437 4281 3714 
    
         5XFAD C S57p 74980 46733 48136 
 
4.82 4.51 4.44 
 
T58p 8963 6741 6183 
 
0.58 0.65 0.57 
 
S57p/T58p 24396 16013 15676 
 
1.57 1.54 1.45 
 
H3 15546 10371 10835 










S57p 6.74 0.49 
 
4.08 0.42 
T58p 0.96 0.08 
 
0.53 0.06 





Multiple reaction monitoring (MRM) data of phosphorylated serine 57 only (S57p), 
threonine 58 only (T58p), and both (S57p/T58p) are shown as raw peak area values and 
normalized to calibration peptide (H3) to account for loading variability and H3 
abundance. Averages (AVG) and standard deviations (SD) were calculated using three 
analytical replicates from three mice for both mixed wild type control and 5XFAD (n=9).  
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4.3 Results and Discussion 
4.3.1 Preparation of Brain Samples for Measurement 
To minimize unwanted loss of phosphorylation, SDS was added to tissue 
homogenates at the very first step of sample processing to arrest enzymatic 
activity. Early addition of SDS also efficiently denatures proteins [121,122] and 
evenly exposes Cys residues in all samples to subsequent reduction and 
alkylation. The main H3 variants, H3.1, H3.2, and H3.3, all contain a cysteine at 
position 110 that is known to undergo disulfide bonding to form an H3 dimer. 
H3.1, in addition, contains a cysteine at position 96 that participates in disulfide 
bonding [123,124]. A challenge to processing brain tissue for MS analysis is its 
high lipid content, which can degrade chromatography performance and 
contribute to ion suppression. The whole brain is approximately 80% lipid by dry 
mass [96] and, therefore, necessitates removal of lipids. Chloroform/methanol 
precipitation of the protein efficiently removed lipids, SDS, salts, and by-products 
alkylation to yield a pure protein pellet. These two major steps, (i) early addition 
of SDS followed by reduction/alkylation of Cys residues and (ii) 
chloroform/methanol precipitation to increase protein purity, ensure sample 
quality compatible with LC-MS/MS analyses, while minimizing processing to 
maintain endogenous phosphorylation. Additionally, all samples were processed 
in parallel to ensure that no artificial loss of phosphorylation would create a bias 
between samples groups and that observed differences between groups were 




4.3.2 Selection of Transitions for MRM 
The main histone H3 variants, H3.1, H3.2, and H3.3, have very close 
homology, which is evidenced by their sequence alignment (Figure 4.1). Initially, 
all selected transitions for peptides containing only S57p, only T58p, or both 
S57p and T58p were used to identify and confirm retention times of peptides in 
each MS chromatogram (Figure 4.2). With the specificity of MRM and consensus 
of six or more transitions for each peptide, peptide identification was performed 
with certainty. The most abundant, unique transition for each peptide was then 
used for quantification using integrated peak area. By selecting the most 
abundant transition for quantification, peak area could be more reproducibly and 
accurately measured. Our measurements using this method of relative 
quantification enable comparison of the level of change in S57 and T58 
phosphorylation in the AD model 5XFAD to control and to EFV-treated 5XFAD. 
4.3.3 APP and Aβ in 5XFAD Brain 
Mice with rapid amyloid deposition (5XFAD) [22] were compared to age- 
and sex-matched wild type C57BL/6J mice. 5XFAD provide an appropriate model 
for AD-related amyloid pathogenesis for the exploration of amyloid-associated 
changes [125]. Aβ was 460 ± 70 pmol/mg total protein in 5XFAD mouse brain, a 
177-fold greater concentration than the 2.6 ± 0.2 pmol/mg in control (Figure 4.3). 
APP was 54 ± 3 pmol/mg in 5XFAD, 13-fold greater than the 4.1 ± 0.5 pmol/mg 
in control (Figure 4.3). The significant increase in APP and Aβ indicates the 






H3.1 1 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGT 45 
H3.2 1 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGT 45 
H3.3 1 ARTKQTARKSTGGKAPRKQLATKAARKSAPSTGGVKKPHRYRPGT 45 
 
H3.1 46 VALREIRRYQKSTELLIRKLPFQRLVREIAQDFKTDLRFQSSAVM 90 
H3.2 46 VALREIRRYQKSTELLIRKLPFQRLVREIAQDFKTDLRFQSSAVM 90 
H3.3 46 VALREIRRYQKSTELLIRKLPFQRLVREIAQDFKTDLRFQSAAIG 90 
 
H3.1 91 ALQEACEAYLVGLFEDTNLCAIHAKRVTIMPKDIQLARRIRGERA 135 
H3.2 91 ALQEASEAYLVGLFEDTNLCAIHAKRVTIMPKDIQLARRIRGERA 135 
H3.3 91 ALQEASEAYLVGLFEDTNLCAIHAKRVTIMPKDIQLARRIRGERA 135 
 
 
Figure 4.1 - Sequence alignment of mouse H3 variants. 
Protein sequence alignment was performed using BLAST. Sequences shown in blue are 
peptides used for quantification. Amino acid residues shown in red indicate differences 
between histone variants to H3.1. Due to sequence homology of quantitative peptides 






Figure 4.2 - Peptide identification by MRM and selection of transitions for 
quantification. 
(A, D, F) Numerous transitions were monitored to determine retention time and confirm 
identity of each peptide. (B, E, H) Spectra of ions used to confirm identity and site of 
phosphorylation. (C, F, I) A single transition was selected from each peptide for 
quantification. *Transition 425.72409.21 had high signal intensity and was removed 





Since the amino acid sequence for Aβ is present in both free Aβ and 
unprocessed APP, it is of interest to compare the level of Aβ to APP to verify that 
Aβ concentration increases were not largely attributed to unprocessed APP. 
Additionally, our inclusion of denaturants facilitated the unfolding and 
solubilization of Aβ for proteolysis, therefore our measurements represent the 
total amount of solubilized Aβ. In control mice, the 4.1 ± 0.5 pmol/mg of APP was 
similarly low in concentration to 2.6 ± 0.2 pmol/mg of Aβ. However, in 5XFAD, 
the 460 ± 70 pmol/mg of Aβ is nearly 9-fold greater than the 54 ± 3 pmol/mg of 
APP, indicating a large increase in Aβ not attributed to unprocessed APP. Our 
measurements confirm that 5XFAD mice produce significantly more Aβ than 
control mice in the brain (Figure 4.3). Our findings validated the use of 5XFAD as 
a model of rapid amyloid pathogenesis for subsequent quantification of 
phosphorylation of S57 and T58 residues. 
5XFAD mice were treated with EFV for three months in parallel to 
untreated 5XFAD controls. EFV was previously shown to directly stimulate the 
activity of brain-specific cholesterol 24-hydroxylase, cytochrome P450 CYP46A1, 
and increase cholesterol turnover [116]. Cholesterol metabolism is closely 
associated with AD pathology; high levels of cholesterol in the brain increase 
susceptibility to AD and advance Aβ plaque formation, while depletion of brain 
cholesterol inhibits production of Aβ [119,120]. Since cholesterol turnover 
reduces cognitive impairment and amyloid pathology [117,118], EFV was chosen 






Figure 4.3 - APP and Aβ in con rol,  X AD, and   V-treated 5XFAD. 
Total amyloid precursor protein (APP) peptide AVIQHFQEK and amyloid beta (Aβ) 
peptide LVFFAEDVGSNK were measured in whole hemisphere homogenates from (A) 
wild type mice (n=3), (B) 5XFAD mice (n=3), and (C) EFV-treated 5XFAD mice (n=3). 
Measurements represent mean ± standard deviation of biological replicates (n=3) using 
three transitions for AVIQHFQEK and four transitions for LVFFAEDVGSNK for absolute 






Figure 4.4 - S57 and T58 phosphorylation in mice. 
(A) Effect of 5XFAD model on S57 and T58 phosphorylation. Phosphorylation was 
measured in whole hemisphere homogenates from mixed wild type mice (n=3) and 
5XFAD mice (n=3). (B) Effect of efavirenz on S57 and T58 phosphorylation in 5XFAD 
mice. Phosphorylation was measured in whole hemisphere homogenates from 5XFAD 
mice (n=3) and 5XFAD mice treated with EFV (n=3). Measurements represent mean ± 
standard deviation of biological and analytical replicates (n=9) normalized to respective 
phosphorylation site in control. **, p < 0.01; ***, p < 0.001.  
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Despite implications of low-dose EFV mitigating effects of AD, EFV-treated 
5XFAD had significantly more Aβ than APP and did not show statistically 
different levels of APP and Aβ compared to 5XFAD without treatment (Figure 
4.3). While the proposed therapeutic low-dose EFV did not cause a reduction in 
Aβ, using greater dosages of EFV to reduce Aβ may not be a practical option for 
long-term treatment of AD. 
4.3.4 S57 and T58 Phosphorylation of 5XFAD Brain 
As compared to C57BL/6J mice, 5XFAD showed a 40% lower level of S57p, 45% 
lower level of T58p, and a 30% lower level of simultaneously phosphorylated 
S57p and T58p (Figure 4.4). The decrease in phosphorylation of S57 and T58 
might have an impact on nucleosome stability. S57 is less than 11 Å from DNA 
and T58 is less than 9 Å from DNA in the crystal structure of the human 
nucleosome, PDB ID: 2CV5 [126] (Figure 4.5). These distances were measured 
with PyMOL Molecular Graphics System (Version 1.7.2, Schrödinger, LLC). 
Phosphorylation of S57 and T58 causes a significant increase in negative charge 
in close proximity to the negatively charged phosphate backbone of DNA (Figure 
4.5C). Furthermore, both residues are on the histone surface and are positioned 
in a turn of a helix-turn-helix motif of the H3 polypeptide chain, highlighting the 
ease of access by modifying enzymes (Figure 4.6). Introduction of phosphoryl 
groups, about 2.5 Å in size, in close proximity to the negatively charged 
backbone of DNA can weaken DNA-histone interactions [113] (Figure 4.6). 
Conversely, dephosphorylation, as observed in 5XFAD (Figure 4.6C), can 
strengthen nucleosome stability and lead to condensed chromatin with reduced 
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gene expression [113], consistent with AD pathology [36,103]. Our 
measurements reveal dephosphorylation of S57 and T58 in 5XFAD, which may 
illustrate specific epigenetic changes that occur in AD. 
The effect of EFV on histone phosphorylation was also measured. Low-
dose EFV treatment of 5XFAD did not show statistically different levels of S57 
and T58 phosphorylation compared to 5XFAD without treatment (Figure 4.4). Our 
findings may indicate that previously reported effects of EFV are not directly 
associated with S57 and T58 phosphorylation. Furthermore, unregulated 
production of Aβ in 5XFAD prior to EFV treatment may have detrimental effects 
on the mice, indicated by low levels of S57 and T58 phosphorylation, which 
persist after three months of EFV treatment. This is an interesting observation for 
AD pathology and may suggest that some epigenetic markers, such as histone 
PTMs, may be less reversible with mild drug treatment after onset of 
neurodegenerative disease. Conversely, it may be that the EFV dose was 








Figure 4.5 - Proximity of H3 S57 and T58 to DNA. 
(A) S57 is less than 11 Å from DNA and (B) T58 is less than 9 Å from DNA. DNA is 
shown in gray, H3 in blue, and S57 and T58 sites in red. Distance measurements were 
performed in PyMOL Molecular Graphics System Version 1.7.2 using the crystal 
structure of the human nucleosome (PDB ID: 2CV5) [126]. (C) Surface view of 
phosphorylated S57 and T58 on histone core (green) in close proximity to the interface 
of the negatively charged phosphate backbone (red) of DNA (gray). All modeling was 
performed in PyMOL and insertion of phosphate groups was performed using a PyMOL 







Figure 4.6 - Location of H3 residues S57 and T58 within nucleosome. 
(A) Core histones (green), with flexible histone tails truncated in structure, is shown 
wrapped in DNA (gray). The S57T58 regions (spheres with oxygen in red and nitrogen in 
blue) are in the turn of a helix-turn-helix motif that brings the residues in close proximity 
to DNA and are easily accessible to kinases and phosphatases. (B) Phosphorylated S57 
and T58 create a repulsive charge-charge interaction with negatively charged DNA, 
weakening the affinity of the nucleosome. (C) Dephosphorylation of S57 and T58 greatly 
reduces negative charge on the histone interface, strengthening the affinity of the DNA-
histone interaction. Modeling was performed using PyMOL Molecular Graphics System 
Version 1.7.2 and the crystal structure of the human nucleosome (PDB ID: 2CV5) [126]. 




 We demonstrated that MRM assay can provide relative quantification of 
phosphorylation of histone H3 residues S57 and T58 in lipid-rich, whole mouse 
brain homogenates. We showed that levels of S57p, T58p, and doubly 
phosphorylated S57 and T58 decrease in 5XFAD mice. This suggests these 
histone PTMs play an epigenetic role in AD pathology and may stabilize 
nucleosomes, causing decreased gene transcription. Additionally, we measured 
effect of low-dose EFV on S57p and T58p, which showed no statistically 
significant changes. Our measurements contribute to the overall understanding 





Chapter 5: Histone PTMs in AD-affected Human Frontal Cortex 
This chapter contains data submitted to Clinical Proteomics for publication. 
5.1 Introduction 
We have identified several sites of histone PTMs in frontal cortex from 
human donors with AD that are differentially abundant compared to age-matched 
normal donors. The majority of PTM and protein measurements in AD research 
are performed in animal models of neurodegeneration, with few studies being 
performed using human brain. While we do not underestimate the potential of 
animal models, it is beneficial to obtain measurements, when possible, in human 
brain tissue affected by AD to confirm changes are truly indicative of AD 
pathology. With our multiple reaction monitoring (MRM) mass spectrometry 
method of PTM quantification, we were able to measure several histone PTMs in 
frontal cortex from humans. Frontal cortex is an ideal neural tissue for 
investigation of PTMs because it is responsible for short-term memory, cognition, 
and decision making, which are all affected by AD, and it is severely damaged in 
late AD [128]. Significant changes in methylation of H2B K108 and H4 R55 and 
ubiquitination of H2B K120 reported herein have not been previously reported in 
frontal cortex from human donors affected with AD. Structural and functional 
effects from these modifications likely have implications in AD pathology and may 





5.2.1 Human Tissue 
Frozen samples of frontal cortex were obtained from Washington 
University School of Medicine Alzheimer’s Disease Research Center (St. Louis, 
MO) as described in Appendix A1.3. Demographic information on the de-
identified donors is summarized in Table 5.1. 
 
Table 5.1 - Donor information. 
Donor ID Age (years) Gender Disease status PMI (h) 
1 90 F Normal 9.5 
2 87 M Normal 6.3 
3 80.7 F Normal 5.5 
4 86.9 M Normal 11.6 
5 87.2 M Normal 12 
6 92.1 F Normal 6 
11 79 M Severe AD 6 
12 73.6 F Severe AD 4 
13 81.2 F Severe AD 4 
14 91 F Severe AD 4.5 
15 72 M Severe AD 1 
16 84 F Severe AD 4.5 
 
Alzheimer’s disease (AD) in frontal cortex was evaluated by the Clinical Dementia Rating 
(CDR) with no dementia representing normal brain and severe dementia representing 
severe AD-affected brain. Post mortem interval (PMI) is defined as the time between 





5.2.2 Purification of Histones from Frontal Cortex for PTM Screening 
To reduce sample complexity for data-dependent screening for PTMs, 
histones were purified from tissue. Frontal cortex tissue from both AD-affected 
and normal donors were carefully cleaned from white matter and blood and 1.1 g 
of cortex was minced. Nuclei isolation and histone purification was performed as 
previously described [129] using nuclei isolation buffer (NIB-250) composed of 15 
mmol/L Tris-HCl (pH 7.5), 15 mmol/L NaCl, 60 mmol/L KCl, 5 mmol/L MgCl2, 1 
mmol/L CaCl2, and 250 mmol/L sucrose. Tissue was added to 10 mL of NIB-250 
containing 10 mmol/L DTT, 10 mmol/L sodium butyrate, and 0.2% NP-40 and 
homogenized on ice with a glass/teflon dounce homogenizer using 10 strokes. 
Homogenate was incubated for 10 min on ice and then centrifuged at 1,000 g for 
7 min at 4 °C. Pellet was washed with NIB containing 10 mmol/L DTT and 10 
mmol/L sodium butyrate, but no NP-40. Pellet was supplemented with 8 mL 0.4 
mol/L H2SO4 and incubated for 2 h at 4 °C with rotation. Sample was then 
centrifuged at 3,400 g for 5 min at 4 °C and resulting supernatant was 
supplemented in a 4:1 (volume ratio) with trichloroacetic acid and allowed to 
precipitate overnight at 4 °C.Pellet was washed with 12 mL of acetone acidified 
with 0.1% volume of hydrochloric acid and centrifuged for 5 min at 3,400 g at 4 
°C. Pellet was washed with 12 mL of pure acetone and centrifuged for 5 min at 
3,400 g at 4 °C. Pellet was air dried for 2 h at room temperature. 1 mL of water 
was added to the pellet and sample was gently rotated to allow for histones to be 
solubilized in the water. Sample was then centrifuged for 5 min at 3,400 g at 
room temperature and histones were collected in the supernatant. Histone 
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concentration was determined using the DC protein assay kit and bovine serum 
albumin as a standard. Histones were stored at -20 °C before further processing. 
The resulting 100 µL histone sample (15.5 µg) was supplemented with 100 µL of 
25 mmol/L NH4HCO3 and 0.1% RapiGest SF (Waters, Milford, MA) then treated 
in a 25:1 mass ratio of histone to trypsin overnight at 37 °C. Following 
trypsinolysis, 0.5% trifluoroacetic acid (TFA) was added and incubated at 37 °C 
for 1 h to cleave acid-labile RapiGest. Samples were then centrifuged at 179,000 
g for 30 min at 4 °C to remove precipitated surfactant. Supernatants were dried 
using a Vacufuge. 
5.2.3 PTM Identification and Selection 
Data-dependent acquisition of histone peptides was performed by LC-
MS/MS using an Agilent 6550 QTOF. Peptides were eluted from an Agilent 
ProtID C18 nanochip (75 µm x 150 mm, 300 nm) over 120 min gradient from 3% 
to 35% acetonitrile containing 0.1% formic acid at a flow rate of 300 nL/min. 
Acquisition method in positive mode used capillary temperature 275 °C, 
fragmentor 180 V, capillary voltage 1950 V, a 300 m/z to 2000 m/z mass window 
at 8 spectra/s scan rate for precursor ions, 1.3 m/z isolation window, and a 80 
m/z to 1700 m/z mass window at 3 spectra/s scan rate for product ions. Collision 
energy (CE) was determined using the formulas [95]: 










Data was searched against the SwissProt database for human proteins 
using both Mascot (MatrixScience) and MassMatrix [130] to identify histone 
peptides and PTMs. Search settings were: precursor mass tolerance, 0.05 Da; 
fragment mass tolerance, 0.05 Da; maximum missed cleavages, 4; variable 
modifications, acetylation of lysine, methylation of arginine and lysine, and 
ubiquitination of lysine; enzyme, trypsin. Both Mascot and MassMatrix were used 
together to reduce false positives based on individual searching algorithms. 
Identifications in consensus with both Mascot and MassMatrix were manually 
confirmed by spectra annotation and using LC retention time analysis [131] with 
MassMatrix. Fragmentation data was then used to develop a transition list for 
MRM. 
5.2.4 Human Frontal Cortex Processing for Quantitative Measurements 
For quantitative measurements, samples were minimally processed (i) to 
reduce loss of native PTMs and (ii) to reduce PTM artifacts caused by sample 
processing. Frontal cortex tissue was carefully cleaned from white matter and 
blood from AD-affected (n=6) and normal (n=6) donors. Tissue (0.2 g) was 
minced and then homogenized in 1 mL of 25 mmol/L NH4HCO3 by sonication at 
50 W using four 10 s continuous cycles (Sonicator 3000, Misonix Inc., 
Farmingdale, NY). Homogenates were centrifuged at 2,000 g for 5 min to remove 
debris. Resulting supernatant was measured for total protein concentration using 
detergent-compatible DC protein assay kit in the presence of 1% SDS and 
bovine serum albumin as a standard. Homogenates were stored at -80 °C. 
Samples of 0.2 mg were supplemented with 20 mmol/L DTT and 1% SDS. After 
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1 h incubation at room temperature to reduce cysteines, 55 mmol/L 
iodoacetamide was added and incubated for an additional 1 h to alkylate 
cysteines. Protein was isolated by chloroform/methanol precipitation. Protein 
pellets were sonicated in 1 mL 25 mmol/L NH4HCO3 and 0.1% RapiGest SF and 
then treated with a 25:1 mass ratio of histone to trypsin overnight at 37 °C. 
Following trypsinolysis, 0.5% TFA was added and incubated at 37 °C for 1 h to 
cleave acid-labile RapiGest. Samples were then centrifuged at 179,000 g for 30 
min at 4 °C to remove precipitated surfactant. Supernatants were dried using a 
Vacufuge. 
5.2.5 PTM Quantification by Multiple Reaction Monitoring 
Dried peptides were reconstituted in 3% acetonitrile, 97% water, and 0.1% 
formic acid. Separation was performed on an Agilent Zorbax Eclipse Plus C18 
RRHD column (2.1 mm x 50 mm, 1.8 µm particle) and multiple reaction 
monitoring (MRM) analysis was performed on an Agilent 6490 iFunnel Triple 
Quadrupole LC/MS system (Santa Clara, CA). Peptides were eluted at a flow 
rate of 200 µL/min using the following gradient of solvent B in solvent A: 3% B for 
3 min, 3% to 30% B in 32 min, 30% to 80% B in 5 min, and 80% to 3% B in 3 
min. Solvent A was water containing 0.1% formic acid and solvent B was 
acetonitrile containing 0.1% formic acid. The acquisition method used the 
following parameters in positive mode: fragmentor 380 V, collision energy 25 V, 
cell accelerator 4 V, electron multiplier 600 V, and capillary voltage 3500 V. 
Selected transitions from fragmentation data were used to confirm the retention 
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time and identity during MRM analysis; the transition most appropriate for 
quantification for each peptide is listed in Table 5.2. 
Chromatographic peaks were integrated for transitions selected for 
quantification and peak areas for peptides were divided by the peak area of a 
non-modified peptide for the respective histone (Table 5.2). Ratios of biological 
replicates and injection replicates were averaged and the average from the 
normal frontal cortex samples was used to normalize the control group to 1.00 
and to normalize the AD-affected group for easy comparison of fold changes. 
Student’s two-tailed t-test was performed to determine the level of statistical 
significance of changes between AD and normal groups. 
 
 






H2A AGLQFPVGR 472.796 (2+) 703.39 (1+, y6) 
H2A (canonical) VTIAQGGVLPNIQAVLLPK 966.08 (2+) 1092.68 (1+, y10) 
H2A (1-A, 2-B, H2Ax) LLGGVTIAQGGVLPNIQAVLLPK 757.80 (3+) 546.84 (2+, y10) 
H2B EIQTAVR 408.73 (2+) 446.27 (1+, y4) 
H2B, K108-methylation LLLPGELAKme 484.31 (2+) 736.46 (1+, b7) 
H2B, K120-ubiquitination AVTKubYTSSK 549.79 (2+) 827.43 (1+, y6) 
H3 DIQLAR 358.21 (2+) 359.24 (1+, y3) 
H3, K4-, K9-acetylation KacQLATKacAAR 535.82 (2+) 772.47 (1+, y7) 
H4 VFLENVIR 495.29 (2+) 501.31 (1+, y4) 
H4, K8-, K12-, K16-
acetylation 
GGKacGLGKacGGAKacR 606.34 (2+) 927.54 (1+, y9) 
H4, K12-, K16-acetylation GLGKacGGAKacR 464.27 (2+) 530.30 (1+, y5) 
H4, R55-methylation ISGLIYEETRme 597.82 (2+) 290.18 (1+, y2) 
 
Modifications (ac) acetylation, (me) methylation, and (ub) ubiquitination of peptides were 






5.3 Results and Discussion 
5.3.1 Selection of Transitions for MRM 
 Initially, histones were purified from normal and AD-affected tissue to 
produce a sample with less complex matrix for improved identification of histone 
peptides in a discovery mode screening. While dynamic exclusion was used 
during MS acquisition, data-dependent analysis benefits from having enrichment 
of the histone targets, particularly when a histone PTM may be only a few 
percent of the total amount of the unmodified peptide. Once peptides were 
identified by Mascot and MassMatrix and manually confirmed using retention 
time analysis and spectra annotation, a transition list was created from abundant 
fragment ions, which was used for MRM. The optimized transitions used for 
quantification are in Table 5.2. 
5.3.2 Preparation of Samples 
 For PTM screening, histones were extensively purified. However, it was 
preferable to minimally process the tissue samples for quantification to evaluate 
differences in AD versus normal frontal cortex because extensive processing 
may cause a loss in PTMs and also introduce processing artifacts, resulting in 
inaccuracy of measurements. These two major steps, (i) early addition of SDS 
followed by reduction/alkylation of Cys residues and (ii) chloroform/methanol 
precipitation to increase protein purity, ensure sample quality compatible with LC-




5.3.3 Reproducibility and Data Quality 
 Selected transitions for quantification had good peak shape and intensity 
as is preferred for quantification (Figure 5.1). However, it is important to establish 
the level of variability in measurements to confirm that observed changes are 
attributed to true biological changes and not an artifact of LC-MS/MS 
performance or sample preparation. To demonstrate our data quality, we first 
performed six replicate injections of the same sample (Figure 5.2A) and 
measured modified H3 peptide KacQLATKacAAR as a ratio to non-modified H3 
peptide DIQLAR. Measured ratios were nearly identical with negligible variation, 
demonstrating LC-MS/MS performance was precise and not a contributor to 
measurement variation. Second, we compared variability between six biological 
samples from normal frontal cortex using the ratio of non-modified H2B peptide 
EIQTAVR to H3 peptide DIQLAR (Figure 5.2B). Histones H2B and H3 are 
present in equal amounts as there is a 1:1 stoichiometry between core histones 
in the nucleosome. Therefore, H2B to H3 should not change between donors or 
sample preparations. Indeed, our measurements confirm that there is negligible 
variation in H2B/H3 between donors, demonstrating that our sample preparation 
results in precision of measurements. Lastly, we monitored the H3 peptide 
KacQLATKacAAR as a ratio to H3 peptide DIQLAR (Figure 5.2C) for the same 
six donors of normal frontal cortex and in the same LC-MS/MS runs as for Figure 
5.2B. Detectable variability across donors for KacQLATKacAAR shows that 
variability in KacQLATKacAAR measurements is due to biological differences in 




Figure 5.1 - Chromatograms of transitions used for quantification. 
Transitions for H2A (purple), H2B (green), H3 (red), and H4 (blue) with non-modified 




Figure 5.2 - Variability in replicate measurements. 
(A) The ratio of modified H3 peptide KacQLATKacAAR to H3 was measured in 6 
replicate injections of a frontal cortex sample from a normal donor and individual ratios 
were normalized to their average (n=6) and plotted to show the negligible variability 
between replicate injections.  (B) The ratio of non-modified H2B to H3 plotted for 
biological replicates from normal donors (n=6) and normalized to the average, showing 
negligible variability between biological replicates for the stoichiometric H2B/H3 ratio. (C) 
The ratio of KacQLATKacAAR to H3 plotted for the average of two injections for each 
biological sample from normal donors (n=6) and normalized to the average for all 
measurements (n=12), showing variability in PTM is attributed to differences in donors 
and not due to inherent variability in MRM.  
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In summary, we established that measured differences between AD and control 
samples described herein are representative of biological variation and that our 
sample preparation and MRM assay is robust and precise. 
5.3.4 Effect of Histone Used for Normalization 
Changes in quantified histone PTMs between AD and normal frontal 
cortex from human donors are presented in Figure 5.3B. For quantification of 
histone PTMs, the peak areas of modified peptides were normalized to the peak 
areas of non-modified peptides from the respective histone. For example, 
ubiquitinated H2B peptide AVTKubYTSSK was normalized to H2B peptide 
EIQTAVR while acetylated H4 peptide GLGKacGGAKacR was normalized to H4 
peptide VFLENVIR. While normalization of PTMs within a protein to the total 
amount of the protein is an accepted practice for quantification [132], it is typically 
not advisable to normalize PTMs within one protein to the total abundance of a 
different protein. Histones, however, are present in a stoichiometric 1:1:1:1 ratio 
of H2A:H2B:H3:H4 in the nucleosome. Due to their equal abundance, using a 
peptide from a single histone for normalization of all measured histone PTMs 
should generate similar quantification results and relative standard deviation 
(RSD) without a bias for using the respective histone that contains the PTM for 
normalization. We performed a series of normalizations, normalizing all 
measured PTMs to a single histone to evaluate the effect of normalization 
(Figure 5.3A). We were able to show that there is a close consensus in RSD 
between H2A, H2B, and H3 normalization. H4 normalization varied in RSD with 
H4 RSD matching that of the other histones or being more or less than that of the 
117 
 
other histones used for normalization. While H4 was often different than the 
consensus RSD for other histones, it did not show bias for H4 PTMs or PTMs of 
other histones. While the histone used for normalization should not have an 
effect, we would expect any effect on normalization to have a bias for normalizing 
PTMs to their respective histone, resulting in lower RSD for H4 PTMs to total H4 
pairs. Additionally, no single histone showed a significantly different RSD when 
used for normalization. The average RSD when PTMs were normalized to their 
respective histones was 19%, while normalizing all PTMs to one histone yielded 
an average RSD of 19% for H2A, 20% for H2B, 19% for H3, and 22% for H4 . 
Overall, we were not able to observe any bias in histone normalization, which 
supports the stoichiometric relationship of histones in the nucleosome and the 





Figure 5.3 - Histone PTMs in frontal cortex. 
(A) Measured peak areas of each quantified peptide were normalized to the peak area 
of different histone subunits. The relative standard deviation (n=12) for each quantified 
peptide in normal and AD frontal cortex is shown grouped by the histone in which the 
peptides are located. (B) Changes in histone PTMs in AD-affected human frontal cortex. 
Measurements were performed using human frontal cortex from normal (n=6) and AD-
affected (n=6) donors (Additional file 1: Table S1) and two experimental replicates per 
donor (n=12 total measurements per condition). Q-peptide transitions are summarized in 
Table 1. Data presented as mean ± SD. PTMs are (ac) acetylation, (me) methylation, 




5.3.5 Implications of Histone PTMs in AD Human Frontal Cortex 
Observed changes in histone PTMs in AD are presented in Figure 5.3B. In 
most sequence variants, histone H2A contains a lysine or arginine residue at 
position 99, however variants 1-A, 2-B, and H2Ax do not contain K/R99. Since 
K/R99 is a potential site for modification, the inability to regulate by K/R99 via a 
reduction in variants that contain this site could be of importance. We did not 
observe any differences in abundance in isoforms with K/R99 or without K/R99, 
indicating turnover of these variants is not present in AD pathology in the frontal 
cortex. Similarly, measurements for K4- and K9-acetylated H3 and K8-, K12-, 
and K16-acetylated H4 did not show statistically significant changes between AD 
and control. We did measure significant changes in PTMs of other sites that are 
associated with structural and functional implications related to AD. 
K12- and K16-acetylated H4 increased 25% in AD. The increase in K12- 
and K16-acetylated H4 could be due to a loss in acetylation of K8, leading to 
tryptic cleavage after K8 and increasing the peptide 9GLGKacGGAKacR17. While 
we did not observe a change in 6GGKacGLGKacGGAKacR17, loss of K5 may 
have increased fragment 6-17, which was simultaneously undergoing a loss of 
K8, resulting in no net change in fragment 6-17. Global deaceylation of histones 
is associated with AD; however, our data suggests that deacetylation may be 
occurring more frequently at the N-terminus of the histone tail. The N-terminal 
regions of histones are rich in glycine residues, which provide a high degree of 
flexibility to histone tails and lack of tertiary structure. Additionally, the high 
abundance of basic residues lysine and arginine contribute to an overall positive 
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charge. Positively charged histone tails and negatively charged DNA form an 
electrostatic interaction that structurally results in the tail region wrapping along 
the DNA backbone, thereby forming a tight nucleosome structure [133]. The 
reduction in net charge, due to the DNA-histone tail interaction, and orientation of 
the extended tail against the nucleosome surface lead to denser, less 
transcriptionally active chromatin [133]. The loss of N-terminal acetylation 
induces this charge interaction and likely results in decreased gene expression in 
the AD frontal cortex. Deacetylation of histones is catalyzed by histone 
deacetylases (HDACs) and there is a growing interest in using HDAC inhibitors 
to slow aberrant deacetylation in brain [31]. Our previous work measured 
absolute concentrations of HDAC isoforms and identified specific isoforms 
associated with AD pathology in various neural tissues [53]. 
While HDAC has demonstrated potential as a prospective AD therapy, 
therapies targeting other histone-modifying enzymes have yet to come forward. 
Other PTMs, such as methylation, are modulated by enzymes with greater 
residue specificity than acetyltransferases and deacetylases. Often times, a 
methyltransferase or demethylase may only act on one site in a histone [39]. This 
specificity may correlate to improved efficacy and safety when targeting enzymes 
for specific methylation sites compared to HDAC inhibition alone. Additionally, 
they may be more efficacious as a combinatorial treatment. H2B methylation at 
K108 decreased 25% and H4 methylation at R55 decreased 35% in AD frontal 
cortex (Figure 5.3B). Both of these sites have been reported to be methylated in 
human cells [134]. To our knowledge, H2B K108 and H4 R55 methylation have 
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not been investigated in AD-affected human frontal cortex. Both H2B K108 and 
H4 R55 are located on the outermost surface of the nucleosome (Figure 5.4A) 
[126], suggesting their accessibility to methyltransferases and demethylases may 
incline them to be used as switches for transcriptional activity. Monomethylation 
is commonly a marker of transcription activation. Since AD is characterized by a 
global repression in gene expression, our observed decrease in several 
methylation sites strongly suggests their role in reducing transcription consistent 
with AD. H4 R55 participates in a complex hydrogen bond network in the 
nucleosome (Figure 5.4B) [126]. H4 residues Q27 and E52 and the I29 backbone 
form a hydrogen bond network that structurally thrusts N25 into a hydrogen bond 
with E73 on neighboring histone H3 [135]. By forming a hydrogen bonding 
network that increases affinity between H3 and H4, the nucleosome becomes 
structurally more stable. However, methylation of H4 R55 likely disrupts this 
bonding network, thereby lessening the H3-H4 interaction and weakening the 
nucleosome [135]. Our observed decrease in methylation of R55 may be a 
mechanism for increasing nucleosome stability and favoring denser chromatin, 
which decreases gene expression. Similarly, H2B K108 is central to a hydrogen 
bond network involving histones H2A, H2B, and H4 (Figure 5.4C) [126]. H2B 
K108 and E105 participate in intra-chain hydrogen bonding which structurally 
positions H2B residues for two interactions between neighboring histones 
favoring nucleosome stability. First, K108 forms a hydrogen bond with E105, 






Figure 5.4 - Location of core PTMs on nucleosome surface. 
H2A (blue), H2B (pink), H3 (yellow), and H4 (green) form an octamer in the nucleosome 
core, which is wrapped by DNA. Nucleosome crystal structure PDB ID: 2CV5 [126] was 
modified using PyMOL Molecular Graphics System (Version 1.7.2, Schrödinger, LLC). 
(A) Methylation sites R55 on H4 and K108 on H3 and ubiquitination site K120 on H2B 
are shown in red. (B) Hydrogen bond network of H4 R55. (C) Hydrogen bond network of 
H2B K108.  
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E105 and E93 can create electrostatic repulsion, however when E105 is 
distanced from E93 and hydrogen bonded to K108, this electrostatic repulsion is 
greatly reduced and H2A and H2B are able nestle together [126]. Second, the 
K108 hydrogen bond with E105 twists the helix-loop-helix, shown in Figure 5.4C, 
to position R99 on H2B directly facing T71 on H4 for a hydrogen bond. This 
hydrogen bond between residues on H2B and H4 strengthen the H2B-H4 
stability. Methylation likely disturbs this H4-H2B-H2A inter-chain network and 
would favor disassembly of the nucleosome. The structural and functional effect 
of our observed decrease in methylation of H2B K108 is consistent with the 
decrease in H4 R55, suggesting methylation of histones is used to down regulate 
transcriptional activity and gene expression in AD pathology. Establishing 
specific sites of histone methylation and their modulation, as described herein, is 
important in characterizing AD pathology. 
H2B ubiquitination at K120 increased 91% in AD (Figure 5.3B). K120 has 
been reported to be ubiquitinated in human cell culture and animal neural tissue 
[134,136,137], but we were unable to find reports measuring ubiquitination of this 
site in AD-affected human frontal cortex. Polyubiquitination of proteins is 
commonly to mark proteins for degradation; however, monoubiquitination of 
proteins is typically used for regulatory functions [46]. After trypsin digestion, a di-
glycine remnant of ubiquitination remains on modified lysine residues, which 
does not allow for differentiation between mono- and polyubiquitination. 
Polyubiquitination of histones is less common, but has been suggested to affect 
the affinity of histone-histone interactions within the nucleosome [45]. 
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Monoubiquitination of histones has been shown to indicate the presence of DNA 
damage [46,47] and to engage in “cross-talk” with methylation of other sites 
[136]. Ubiquitination of H2B K120 has been shown to be inversely related to 
methylation of H3 core residue K79 [136]. While we did not detect methylation of 
H3 K79, we did detect a decrease in methylation of other core residues H2B 
K108 and H4 R55. Additionally, site H2B K120 is an easily accessible site for 
ubiquitin ligases as it is located on the outermost surface of the nucleosome core 
and distant from the histone-DNA interface (Figure 5.4A) [126], an important 
consideration for a relatively large, 8.5 kDa PTM. Abnormal accumulation of 
ubiquitinated proteins other than histones in AD has been reported [138], 
suggesting ubiquitination in AD may extend beyond histones and the epigenome. 
5.4 Conclusions 
 Histone PTMs have been implicated in many biological functions and 
diseases and serve an important role in epigenetic regulation of gene expression. 
Aberrant modulations in histone PTMs have been suggested to occur in brain as 
part of AD pathology. Histone PTMs that were found to be significantly different 
in AD frontal cortex were decreases in methylation of H2B K108 and H4 R55 and 
an increase in ubiquitination of H2B K120. Changes of these sites have not been 
previously reported in AD-affected frontal cortex in humans. Additionally, 
acetylated H4 peptide 9GLGKacGGAKacR17 increased in abundance, which may 
indicate N-terminal loss of acetylation of K5 and K8. Structural effects induced by 
changes in these PTMs likely alter gene expression in the brain. Future work to 
evaluate the combinatorial effect of these PTMs on gene expression and other 
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specific functional roles may prove to be important in elucidating the pathology of 
AD. Moreover, the PTMs described herein could be used to identify specific 
histone-modifying enzymes to serve as drug targets for the treatment of AD, a 
disease which currently does not have any approved therapies to slow disease 





Chapter 6: Conclusions and Significance 
 QconCATs are a unique standard for quantification containing Q-peptides. 
We have shown that incorporation of natural flanking sequences, while not 
directly used for quantification, appear to aid in the reliability of quantification. 
Based on our findings, the length of natural amino acid flanking sequences in the 
+0 to +6 amino acid residue range is not the only factor affecting trypsin 
cleavage. The amino acid composition within this range also affects the flanking 
sequence; however, our results are not entirely explained by Keil rules of trypsin 
cleavage. Future studies comparing the proximity of positively or negatively 
charged residues near the cleavage site and natural flanking sequence could 
increase our understanding of this phenomenon of cleavage variability. In light of 
the amino acid composition, it is best to provide more natural amino acids in the 
flanking residues when appropriate for improved quantification reliability. 
Use of QconCATs for multiplexed quantification of HDAC isoforms were 
obtained in three different tissues: human frontal cortex, human retina, and whole 
mouse brain. This method of protein quantification is appropriate in diverse types 
of tissues, including tissues abundant in lipids. In human frontal cortex, HDAC1,2 
decreased, HDAC5 increased, and HDAC6 had negligible change in 
concentration in AD. In human retina, the concentration of all detected HDACs 
decreased in both AD and AMD retina. In whole mouse brain, the profile varied 
from human brain with HDAC3 and HDAC4 abundance being greater in mouse. 
HDAC1,2 concentrations decreased in both human frontal cortex and retina, but 
showed no change in mouse. While mouse models are commonly used for 
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neurodegenerative research, disparity in HDAC profiles and changes in disease 
state compared to human frontal cortex tissue indicates that measurements in 
humans are beneficial when possible. This method of quantification is practical 
and useful tool for disease pathology and can be used for other tissues and 
disease conditions. 
 Relative quantification by MRM of histone PTMs in mouse and human 
brain revealed unique changes in AD pathology. Phosphorylation of histone H3 
residues S57 and T58 decreased in 5XFAD mice, suggesting these histone 
PTMs play an epigenetic role in AD pathology and may stabilize nucleosomes. A 
mouse model was used for phosphorylation data because phosphorylation is a 
very labile modification that is lost during the lengthy post-mortem interval for 
human neural tissue. The effect of low-dose EFV, a stimulator of cholesterol 
hydroxylase CYP46A1 activity, on S57p and T58p showed no statistically 
significant changes in 5XFAD brain. In AD human frontal cortex, decreases in 
methylation of H2B K108 and H4 R55 and an increase in ubiquitination of H2B 
K120 were measured. Measurements of these sites have not been previously 
reported in AD-affected frontal cortex in humans. Acetylated H4 peptide 
9GLGKacGGAKacR17 increased concentration, which may indicate N-terminal 
loss of acetylation at K5 and K8. 
Changes in PTMs can have structural effects which likely alter gene 
expression in the brain. We have proposed several structural mechanisms for 
how histone PTM modulation can affect gene expression. Future work could be 
performed to investigate the combinatorial effect of PTMs on gene expression. 
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My efforts to perform intact profiling of histone PTMs were unsuccessful. The 
heterogeneity of histone variants and complexity of PTM profiles proved 
challenging for spectral deconvolution software, which resulted in large variability 
of PTM abundances between software packages and acquisition conditions. 
Other research laboratories are developing in-house software to handle the 
challenges related to intact histone PTM profiling, which should prove helpful in 
future intact histone studies using MS. 
Histone PTM measurements can describe specific functional roles, which 
could prove to be important in elucidating AD pathology. Perhaps more important 
is the use of histone PTMs to identify specific histone-modifying enzymes, which 
could serve as drug targets for AD treatments. Currently, there are no approved 
therapies to slow or prevent AD progression, highlighting the importance of drug 




Appendix 1: Approvals and Funding 
A1.1 Disclaimer 
Certain commercial materials, instruments, and equipment are identified in 
this dissertation in order to specify the experimental procedure as completely as 
possible. In no case does such identification imply a recommendation or 
endorsement by the National Institute of Standards and Technology nor does it 
imply that the materials, instruments, or equipment identified are necessarily the 
best available for the purpose. 
A1.2 Funding 
Human frontal cortex was funded by the Washington University School of 
Medicine Alzheimer’s Disease Research Center’s National Institute of Aging 
grant (P50 AG005681). Retina studies were funded by the National Institutes of 
Health grant EY018383 (to I.A. Pikuleva). Mouse studies were funded by the 
U.S. Public Health Service grant GM062882 (to I.A. Pikuleva). 
A1.3 Use of Human Tissue 
Frozen samples of frontal cortex were obtained from Washington 
University School of Medicine Alzheimer’s Disease Research Center (St. Louis, 
MO). Human frontal cortex was collected in accordance with guidance from the 
Washington University Human Research Protection Office (HRPO number: 89-
0556). We consulted the Washington University HRPO, which determined that 
Institutional Review Board (IRB) oversight was not required for these studies and 
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waived the need for IRB approval. In the state of Missouri, individuals can give 
prospective consent for autopsy. Our participants provided this consent by 
signing the hospital’s autopsy form. If the participant does not provide future 
consent before death, the DPOA or next of kin provide it after death. Human 
retina use conformed to the Declaration of Helsinki and had been approved by 
the Ethical Committee at Case Western Reserve University. Eyes were acquired, 
characterized and dissected as described [94]. The neural retina was isolated, 
flash-frozen in liquid nitrogen, and stored at -80 °C until analyzed. Handling of 
tissues for sample processing conformed to University of Maryland regulations. 
All data were analyzed anonymously. 
A1.4 Use of Mice 
 All animal-handling procedures were performed at Case Western Reserve 
University and were approved by the Institutional Animal Care and Use 
Committee at Case Western Reserve University and conformed to the standards 
of the U.S. Public Health Service Policy on Humane Care and Use of Laboratory 
Animals and recommendations of the American Veterinary Association Panel on 
Euthanasia. Mice were housed in the Animal Resource Center at Case Western 
Reserve University and maintained in a standard 12 h light/12 h dark cycle 
environment. Water and food were provided ab libitum. Mice were sacrificed by 





A1.5 General Materials 
 The DC Protein Assay kit was purchased from Bio-Rad Laboratories 
(Hercules, CA). RapiGest SF surfactant was from Waters (Milford, MA), Trypsin 
(T0303, Type IX-S from porcine pancreas) and all other chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO).  
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Appendix 2: Additional Data 







HDAC1 482 Q13547 Canonical 
    
HDAC2 488 Q92769 Canonical 
    
HDAC3 Isoform 1 428 O15379-1 Canonical 
HDAC3 Isoform 2 429 O15379-2 1-15: MAKTVAYFYDPDVGN → MIVFKPYQASQHDMCR 
    
HDAC4 1084 P56524 Canonical 
    
HDAC5 Isoform 1 1122 Q9UQL6-1 Canonical 
HDAC5 Isoform 2 1037 Q9UQL6-2 684-768: Missing 
HDAC5 Isoform 3 1123 Q9UQL6-3 7-7: S → SA 
    
HDAC6 1215 Q9UBN7 Canonical 
    
HDAC7 Isoform 1 952 Q8WUI4-1 Canonical 
HDAC7 Isoform 2 480 Q8WUI4-2 
1-472: Missing, 473-520: LAQGGHRPLS...TPARTLPFTT → 
MQACVGVRGV...WVPALTLAPA 
HDAC7 Isoform 3 915 Q8WUI4-3 227-263: Missing 
HDAC7 Isoform 4 922 Q8WUI4-4 227-256: Missing 
HDAC7 Isoform 5 991 Q8WUI4-5 1-1: M → MHSPGADGTQVSPGAHYCSPTGAGCPRPCADTPGPQPQPM 
HDAC7 Isoform 6 974 Q8WUI4-6 1-1: M → MHSPGAGCPRPCADTPGPQPQPM 
HDAC7 Isoform 7 954 Q8WUI4-7 
1-1: M → 
MHSPGADGTQVSPGAHYCSPTGAGCPRPCADTPGPQPQPM, 227-263: 
Missing 
HDAC7 Isoform 8 1014 Q8WUI4-8 
1-1: M → 
MSDLRKRELGALFTSRGTGGVEWDGTQVSPGAHYCSPTGAGCPRPCA
DTPGPQPQPM, 892-952: SKYWGCMQRL...LVEEEEPMNL → 
MGALTLSQIP...QGLTKKKWRQ 
HDAC7 Isoform 9 425 Q8WUI4-9 1-527: Missing 
HDAC7 Isoform 10 614 Q8WUI4-10 1-338: Missing 
    
HDAC8 Isoform 1 377 Q9BY41-1 Canonical 
HDAC8 Isoform 2 272 Q9BY41-2 
248-272: 
LKEVYQAFNPKAVVLQLGADTIAGD → RTSCPKSRPVEAAAAACLPHLH
SLV, 273-377: Missing 
HDAC8 Isoform 3 163 Q9BY41-3 
147-163: DEASGFCYLNDAVLGIL → RDVCVCGTLQGILKKSK, 164-377: 
Missing 
HDAC8 Isoform 4 286 Q9BY41-4 56-146: Missing 
HDAC8 Isoform 5 256 Q9BY41-5 
246-272: SVLKEVYQAFNPKAVVLQLGADTIAGD → RYEPPAPNPGL, 
273-377: Missing 
    
HDAC9 Isoform 1 1011 Q9UKV0-1 Canonical 
HDAC9 Isoform 2 923 Q9UKV0-2 487-574: Missing 
HDAC9 Isoform 3 590 Q9UKV0-3 
575-590: PFLEPTHTRALSVRQA → VIGKDLAPGFVIKVII, 591-1011: 
Missing 
HDAC9 Isoform 4 879 Q9UKV0-4 








HDAC9 Isoform 6 1025 Q9UKV0-6 
88-88: K → KLQQ, 218-261: Missing, 1006-1011: 
MSLKFS → KYWKSVRMVAVPRGCALAGAQLQEETETVSALASLTVDVE
QPFAQEDSRTAGEPMEEEPAL 
HDAC9 Isoform 7 1069 Q9UKV0-7 
88-88: K → KLQQ, 1006-1011: 
MSLKFS → KYWKSVRMVAVPRGCALAGAQLQEETETVSALASLTVDVE
QPFAQEDSRTAGEPMEEEPAL 
HDAC9 Isoform 8 588 Q9UKV0-8 
1-1: 
M → MMSSPAQPDLMWNLVPWVLFCGCCRIFPDGVAGREQLLAQQRM, 
218-261: Missing, 575-590: 
PFLEPTHTRALSVRQA → VIGKDLAPGFVIKVII, 591-1011: Missing 
    
HDAC10 Isoform 1 669 Q969S8-1 Canonical 
HDAC10 Isoform 2 649 Q969S8-2 252-271: Missing 
HDAC10 Isoform 4 658 Q969S8-4 
612-669: 
NSTPQLAGIL...MLQCHPHLVA → VSWAGWRCCG...GPGAEWRGTS 
HDAC10 Isoform 5 396 Q969S8-5 252-301: Missing, 447-669: Missing 
    
HDAC11 Isoform 1 347 Q96DB2-1 Canonical 
HDAC11 Isoform 2 296 Q96DB2-2 1-28: Missing, 85-107: Missing 
 
HDAC (Homo sapiens) Sequences (UniProtKB) 
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